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Chapter I 
INTRODUCTION 
Activation of plasminogen to plasmin by urokinase 
plasminogen activator may play an essential role in tumor 
cell invasion and metastasis. Plasmin is capable of 
digesting the extracellular matrix and basement membrane. 
It exerts its proteolytic action either directly by 
degrading glycoproteins, such as laminin, fibronectin and 
proteoglycans or indirectly by activating procollagenases 
to collagenases. Collagenases which degrade collagen, a 
major structural protein of basement membrane, are 
believed to contribute to the ability of a tumor cell to 
metastasize. Therefore it has been suggested that 
urokinase plasminogen activator might be the essential 
proteolytic enzyme to initiate the cascade of protease 
activation that results in tumor cell invasion and 
metastasis. 
The goal of this dissertation was to study the 
role of urokinase plasminogen activator in the metastatic 
1 
process by a direct approach at the gene level. This 
study was carried out by increasing the production of 
urokinase activity or inhibiting endogenous urokinase 
production by means of the urokinase gene modification in 
tumor cells and testing the metastatic potential of the 
modified cells. 
The results of this study may address the role of 
the secreted form of urokinase in the later steps of the 
metastatic process as well as in the full metastatic 
process. 
2 
Chapter II 
REVIEW OF THE LITERATURE 
TUJ:Dor Cell Metastasis 
Tumor cell metastasis is a transfer of malignant 
tumor cells from the primary site of tumor formation to 
distant organs, and is the major cause of cancer deaths. 
The metastasis of tumor cells is a complex process which 
involves multiple steps. 
At the first step of metastasis, primary tumor cells 
invade through the extracellular matrix and basement 
membrane, spread into adjacent normal tissue, intravasate 
through the capillary endothelial walls, and are 
eventually released into the circulation. Few tumor cells 
survive the transit through the circulation. Those tumor 
cells that do survive arrest in the capillary beds of 
distant organs and extravasate from the capillaries 
through the basement membrane and extracellular matrix 
into the surrounding normal tissue. At the final step of 
metastasis, the extravasated tumor cells grow and give 
rise to secondary tumor deposits. 
During the intravasation and extravasation steps, 
tumor cells must invade a variety of extracellular 
matrices and basement membranes in order to enter the 
underlying interstitial stroma. The extracellular matrix 
is composed of a dense lattice of interstitial collagens 
and elastin fibers embedded within a ground substance 
consisting of fibronectin, other glycoproteins, and 
proteoglycans. The basement membrane is composed of type 
IV collagen, laminin, other specific glycoproteins, and 
heparan sulfate proteoglycans. 
4 
A three-step theory has been proposed by Liotta et 
al. (1986) to explain the sequence of tumor cell invasion 
to the extracellular matrix. The first step is tumor cell 
attachment to the matrix by cell surf ace receptors that 
specifically bind components of the matrix, such as 
laminin. Laminin forms a bridge between the cell surface 
laminin receptor and type IV collagen in the basement 
membrane. The second step of tumor cell invasion is the 
local degradation of the matrix by proteolytic enzymes. 
These are produced by tumor cells or host cells that have 
been induced by tumor cells. The third step is the tumor 
cell locomotion into the region of matrix modified by the 
proteolytic enzymes. Thus the degradation of the above 
5 
tissue barrier by proteolytic enzymes is a part of the key 
step of tumor cell invasion and, in turn, metastasis. 
proteases Involved in Tumor Cell Invasion 
Due to the complexity of the tissue barriers that 
tumor cells must cross in the invasion process, the 
degradation of the matrix may require several proteolytic 
enzymes. The proteolytic enzymes, which have been 
implicated in this step are collagenases, particularly 
type IV, endoglycosidases, cathepsin B-like thiol 
proteinases, and plasminogen activators (Nicolson, 1982). 
A cathepsin B-like proteinase can degrade several 
components of the extracellular matrix such as denatured 
collagen, fibronectin and proteoglycan (Sloane and Honn, 
1984). In addition, it has been suggested that cathepsin 
B-like proteinase might have the potential to activate 
latent type IV collagenase (Sloane et al., 1986). 
Increased amounts of cathepsin B-like thiol proteinase 
have been found in solid tumors (Poole et al., 1980; 
Recklies et al., 1980; Rinderknecht and Renner, 1980; Ryan 
et al., 1985), transformed cell (Myra-y-Loopez et al., 
1985), and tumor cells in culture (Sloan et al., 1981; 
Sloane et al., 1982; Ryan et al., 1984). However, there 
\ 
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are contradictory results which do not find any 
correlation between cathepsin B-like activity and 
metastatic potential (McLaughlin et al., 1983). Others 
have reported that cathepsin B-like activity is negatively 
correlated with transformation (Dolbeare et al., 1980; 
Morgan et al., 1981). Inhibitors of cathepsin B placed in 
high steady-state concentrations within an animal model 
for metastasis failed to show any inhibition of metastasis 
(Ostrawski et al., 1986). 
Endoglycosidases cleave heparan sulfate from matrix 
proteoglycans. Heparan sulfate interacts with matrix 
macromolecules, such as collagens and fibronectin, and 
plasma membrane attachment sites. Therefore, 
endoglycosidases have also been shown to be involved in 
tumor invasion and metastasis (reviewed by Goldfarb and 
Liotta, 1986). 
Interstitial collagenases hydrolyze collagen types 
I, II, and III of the extracellular matrix. Several 
investigators reported a positive correlation between 
tumor cell secretion of interstitial collagenase by mouse 
primary tumor cells and lung metastasis (Tarin et al., 
1982). Another study showed the invasion of a chick 
chorioallantoic membrane by human choriocarcinoma cell 
lines correlated well with the production of collagenase 
but did not correlate with secretion of plasminogen 
activator or cathepsin B (Sekiya et al., 1985). 
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The major structural protein of basement membrane, 
type IV collagen, is not degraded by the interstitial 
collagenase, but by type IV collagenase (Salo et al., 
1982). Type IV collagenase is secreted in a latent form 
and shown to be activated by plasmin in vitro (Werb et 
al., 1977; Paranjpe .§..t al., 1980; Gross et al., 1982; He 
et al., 1989). Enhanced levels of type IV collagenase has 
been shown in malignant tumor cells (Liotta et al., 1986; 
Goldfarb et al., 1986). Positive correlation between type 
IV collagenase activity and the pulmonary metastatic 
potential has been demonstrated in Bl6 melanoma cell lines 
(Liotta et al., 1980) and breast cancer cell lines 
(Nakajima et al., 1986). 
Plasminogen activator (PA) is a serine protease 
which converts the inactive proenzyme plasminogen to 
plasmin. The plasminogen, is ubiquitous in the blood and 
tissue spaces. Plasmin can degrade many components of the 
extracellular matrix in vitro such as proteoglycans 
(Mochan and Keler, 1984), fibronectin (Liotta et al., 
1981; Kramer et al., 1982), and laminin (Liotta et al., 
1981; Boyd et al., 1989). Plasmin has also been shown to 
activate procollagenase to collagenase in vitro, including 
8 
type IV collagenase, which degrades type IV collagen (Werb 
gt al., 1977; Paranjpe et al., 1980; Gross et al., 1982; 
He et al. 1989). Therefore, plasminogen activator, via 
activation of plasminogen, may have a central role in 
initiating cascade reactions that degrade the molecules 
composing the barriers which tumor cells must cross during 
metastasis. The details of plasminogen activator activity 
in tumor cell metastasis will be discussed separately. 
Two distinct types of plasminogen activators are 
known, tissue-type plasminogen activator and urokinase 
type. They are genetically and immunologically distinct 
forms. The two proteins have different amino acid 
sequences, molecular weights, subunit structures and 
catalytic parameters such as affinity to fibrin. Tissue-
type plasminogen activator is released from the 
endothelial cells of the blood vessels and urokinase-type 
plasminogen activator is synthesized in kidney cells and 
released from the renal tubules. Immunological 
characterization has shown that most tumor cells produce 
urokinase-type plasminogen activator rather than tissue-
type (reviewed by Dano et al., 1985). There are some 
exceptions where tissue-type plasminogen activator was 
demonstrated in breast tumor cells induced by carcinogens, 
in melanoma cells (Dano et al., 1985), and several other 
tumor cell lines (Quax et al., 1990). In general though 
tissue-type plasminogen activator appears to be involved 
in fibrinolytic function of the cell, such as lysis of 
fibrin clots, and urokinase-type activity is involved in 
cell migration and tumor cell metastasis. 
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In this report, the term "plasminogen activator" is 
used when unable to identify which type of activator is 
being studied. The term "urokinase" is used when the 
basis of its origin is from the urokinase plasminogen 
activator identified by the urokinase plasminogen 
activator gene or evaluated by immunological assays. 
Tissue-type plasminogen activator is referred to as 
"tissue PA". 
Biochemistry of Urokinase 
The urokinase gene has been isolated and sequenced 
from human (Heyneker et al., 1983; Riccio et al., 1985; 
Nagai et al., 1985), mouse (Degen et al., 1987), pig 
(Nagamine et al., 1985), and chicken (Leslie et al., 
1990). Comparison of the human urokinase gene and the 
porcine, murine, or chicken gene has shown an extensive 
homology (72-79% nucleotide sequence identity) throughout 
the introns and exons (Degen et al., 1987). The four 
10 
urokinase genes are also similar in size: human, 6388 base 
pairs: porcine, 5852 base pairs; murine, 6710 base pairs; 
and chicken, 8158 base pairs (Degen et al., 1987). The 
human urokinase gene is located on the long arm of 
chromosome 10 (Tripputi et al., 1985), while human tissue 
PA is on chromosome 8 (Blasi et al., 1986). The human 
urokinase gene consists of 11 exons and 10 introns (Riccio 
et al., 1985). The mRNA of human urokinase is shown to be 
~ ~ 
2.5 Kb and the cDNA is composed of 1293 base pairs (Verde 
et al., 1984). Human urokinase is a glycoprotein (Holmes 
et al., 1985; Ricco et al., 1985) while mouse urokinase 
contains no N-glycosylation site (Belin et al., 1985). 
Urokinase is synthesized as a single-chain 
preprourokinase composed of 431 amino acids as shown by 
its cDNA size and has a molecular weight of 54 Kd (Salerno 
et al., 1984). It contains a signal leader sequence of 20 
amino acids which is removed during protein synthesis 
(Pennica et gl., 1983). Urokinase is secreted as an 
inactive single-chain prourokinase zymogen of 411 
residues. However, some investigators reported that 
prourokinase purified from certain cell lines demonstrated 
catalytic activity (Stumpt et al., 1986; Ellis et al., 
1987). The single-chain prourokinase is activated by a 
proteolytic cleavage which removes one amino acid, lysine, 
at position 158. Thus the activation generates a two-
chain urokinase molecule (A-chain and B-chain) held 
together by one disulfide bond (Gunzler et al., 1982). 
The activation is mediated by many compounds such as 
plasmin (Dano et al., 1985), plasma kallikrein (Ichinose 
et al., 1986), factor XIIa (Ichinose et al., 1986), 
~ ~ 
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trypsin (Eaton et al., 1984), and thrombin (Eaton et al., 
1984). Plasmin appears to be the most efficient activator 
(Eaton et al., 1984; Ichinose et al., 1986). At certain 
concentrations, thrombin has been found to inactivate 
prourokinase by cleaving arg-156 and phe-157 (van 
Hinsbergh et al., 1987). The active urokinase can be 
further cleaved by plasmin to form a still active 33 Kd 
molecule (Stump et al., 1986). Whether the 33 Kd 
urokinase has specific function is not known. 
Urokinase consists of five distinctive domains, 
known as the signal domain, growth factor domain, kringle 
domain, connecting domain, and catalytic domain (Verde et 
al., 1984). The growth domain is homologous to epidermal 
growth factor, alpha transforming growth factor, 
coagulation factors IX and X, and prothrombin (Anson et 
al., 1984; Fernlund et al., 1982). The homology to growth 
factors might suggest a growth promoting activity of 
urokinase in certain cell lines (Kirchheimer et al., 
12 
l987). The kringle domain is also present in other 
zymogens, such as prothrombin (Magnusson et al., 1976) and 
plasminogen (Sottrup-Jensen et al., 1978). The catalytic 
domain carries the typical active site of the serine 
proteases. Comparison of the amino acid sequence of 
tissue PA and urokinase shows that two domains of the 
tissue PA are missing in urokinase. The first missing 
domain is the finger-like domain which may be responsible 
for the high affinity of tissue PA for fibrin (Banyai et 
al., 1983) and explains the greater fibrinolytic effect of 
tissue PA than of urokinase. The second missing domain in 
urokinase is the second kringle domain of tissue PA. 
The production of urokinase is affected by several 
compounds such as hormones, growth factors, cAMP, and 
tumor promoters. It was shown that calcitonin and 
vasopressin in porcine kidney cells (Nagamine et al., 
1983) and estrogen in breast carcinoma cells (Mira-y-Lopez 
and Ossowski, 1987) induced urokinase mRNA expression. 
Glucocorticoid has been shown to depress the expression of 
urokinase activity in cultured cells (Busso et al., 1987). 
Dexamethasone also decreased the urokinase mRNA levels in 
normal and several malignant tumor cells (Medcalf et al., 
1986). Growth factors, such as epidermal growth factor 
(EGF) (Boyd, 1989; Niedbala and Sartorelli, 1989), 
13 
platelet-derived growth factor (PDGF) (Stoppelli et al., 
l986), and interferon (IFN-gamma) (Collart et al., 1986) 
increased the levels of urokinase rnRNA in cultured cancer 
cells. Transforming growth factor beta gave dual effects, 
in that it stimulated urokinase secretion in certain 
malignant cell lines (Keski-Oja gt al., 1988) and it 
decreased the secretion of urokinase in bovine endothelial 
cells (Saksela et al., 1987). The transcriptional 
increase of urokinase by hormone or growth factor is 
mediated through the cAMP pathway (Saksela and Rifkin, 
1988). The 5'-nontranscibed regions of murine, porcine, 
and human urokinase genes were found to contain 
dodecanucleotides homologous to cAMP regulatory sequences 
(Degen et al., 1987; Riccio et al., 1985; Nagamine et al., 
1985). The tumor promoter, phorbol myristate acetate 
(PMA) also increased urokinase rnRNA synthesis in various 
carcinoma cells (Kelly et al., 1983; Degen et gl., 1985; 
Collart et al., 1986), transformed cells (Belin et al., 
1984), and chicken embryo fibroblasts (Bell et al., 1990). 
The increase of urokinase rnRNA level by PMA stimulation 
was parallel to the increase of c-myc transcription 
(Stoppelli et al., 1986). The increase occurred within 30 
minutes and peaked 2-4 hour after the PMA treatment 
(Stoppelli et al., 1986). 
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The regulation of urokinase activity is also 
modulated by the urokinase specific cell surface receptor. 
Another regulatory mechanism for urokinase activity is the 
secretion of plasminogen activator inhibitors (PAis). 
Three of the inhibitors, PAI-1, PAI-2, and protease nexin 
are reported to regulate plasminogen activator activity by 
rapid inhibition in vivo (Saksela and Rifkin, 1988). 
Urokinase can regulate a variety of physiological 
events that require extracellular proteolysis, such as 
fibrin clot lysis, tissue remodeling, and cell migration 
(reviewed by Dano et al., 1985). Proteolytic degradation 
of extracellular matrix components starts with activation 
of plasminogen by plasminogen activator, subsequently the 
formation of plasmin, and activation of procollagenase to 
collagenase by plasmin as discussed previously. 
Involvement of urokinase in cell migration is observed in 
vitro. It was shown that the continuously migrating, 
wounded endothelial cells have increased urokinase 
activity (Pepper et al., 1987). Another physiological 
process involving urokinase may be angiogenesis. 
Urokinase has a function in the formation of new blood 
vessels supplying the newly formed tumor with nutrients 
required for rapid growth (d'Amore, 1988; Goldfarb et al., 
1986). Lastly, urokinase may be involved in ovulation. 
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Hormones associated with ovulation such as follicle 
stimulating hormone (FSH) and luteinizing hormone (LH), 
stimulate plasminogen activator (Ny et al., 1985; canipari 
et al., 1987). The regulation of urokinase activity is 
also shown in pathological processes such as inflammation, 
pemphigus, cancer, and metastasis (Dano et al, 1985). 
urokinase and Tumor Cell Metastasis 
Indirect evidence in support of a role for urokinase 
in metastasis has been shown by multiple studies and is 
reviewed by Dano et al. (1985). An increase in urokinase 
gene expression or an enhanced urokinase synthesis/ 
secretion have been observed in metastatic variant cell 
lines such as lung and breast carcinomas (Sappino et al., 
1987), mammary adenocarcinomas (Ramshaw et al., 1986; 
Pereyra-Alfonso et al., 1988; Burtin et al., 1987), Lewis 
lung carcinoma (Eisenbach et al., 1985), mammary carcinoma 
(Pauli et al., 1987), human malignant melanoma (Markus et 
al., 1984), and murine fibrosarcoma (Nagy and Grdina, 
1989). Furthermore, many of the solid tumors of lung 
(Markus et al., 1980), prostate (Kirchheimer et al., 1985; 
Camiolo et al, 1987; Gaylis et al., 1989), breast (Duffy 
et al., 1988), stomach (Szczepanski et al., 1982), 
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digestive tract (Noshino et al., 1988), and colon (de 
Bruin et al., 1987) showed increased secretion of 
urokinase as compared to their untransformed counterparts. 
Treatment of cells with tumor promoters (Degen et al., 
1985; Stoppelli et al., 1986), tumor viruses (Unkeless et 
al., 1973, Skriver et al., 1982), and src oncogene product 
(Bell et al., 1990) also increased the gene expression or 
enhanced the secretion of urokinase from cells in vitro. 
There have been a number of studies that show a 
correlation between plasminogen activator production and 
metastasis in murine Bl6 melanoma cell lines. Carlsen et 
al. (1984) isolated clonal tumor cell populations which 
produced various levels of plasminogen activator activity 
and determined the metastatic potential of the isolated 
clones by a lung colonization assay. Their results showed 
a strong correlation between production of plasminogen 
activator activity and metastatic potential. Wang et al. 
(1980) also demonstrated that murine Bl6-Fl0 cells, a 
highly metastatic subline of the Bl6 cell line, produced a 
significantly greater amount of plasminogen activator 
activity than the Bl6-Fl subline of lower metastatic 
potential. This result, however, is in contrast to the 
work of Nicolson et al. (1976) who found that there was 
essentially no difference in plasminogen activator 
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activity between B16 variant cell lines. 
A recent study showed that transf ected mouse L 
cells expressing the human urokinase gene demonstrated an 
increased degradation of extracellular matrix protein and 
invasion of a Matrigel basement membrane. This work 
indicated that urokinase expression ,may be sufficient to 
provide an invasive phenotype in the cell (Cajot et al., 
1989). 
Immunocytochemical studies have also been used to 
indicate the importance of urokinase activity in tumor 
cell metastasis (Pollanen et al., 1987). Skriver et al. 
(1984) reported an increased urokinase level by means of 
immunohistochemical staining in areas close to or in 
contact with normal cells of the surrounding tissue being 
invaded by the tumor cells. 
Since type IV collagen is a major constituent of 
basement membrane, it has been considered as an important 
substrate for tumor invasion. Type IV collagenase, which 
is activated from procollagenase by plasmin, degrades type 
IV and type V collagen and is therefore believed to have 
an important role in the invasion of tumor cells through 
the extracellular matrix and basement membrane (Liotta et 
al., 1980; Goldfarb and Liotta, 1986; Reich et al., 1988; 
Schultz et al., 1988). 
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The human tissue inhibitor metalloproteinase 
(TIMP), a glycoprotein with a molecular weight of 28,000, 
is an inhibitor of metalloproteinases such as type I 
collagenase, type IV collagenase, and stromelysin. TIMP 
has been shown to inhibit lung colonization by Bl6-Fl0 
cells in vivo (Schultz et al., 1988). Similar results 
were reported with a synthetic collagenase inhibitor that 
reduced the lung lesion in the same system (Reich et al., 
1988). In addition, Khokha et gl. (1988) found that 
transfection of an antisense RNA, complementary to the 
mRNA encoding the collagenase inhibitor (TIMP), changed 
the non-metastatic and non-tumorigenic mouse 3T3 
fibroblasts, to the metastatic and tumorigenic phenotype 
that has the ability to colonize the lungs of nude mice. 
Whereas the majority of reports support a positive 
correlation between metastatic potential and urokinase 
activity, there exist other reports which show a lack of 
such a correlation. One report stressed that the only 
proteinase secreted by malignant tissue was the cathepsin 
B-like thiol proteinase (Rechlies et gl., 1980). Others 
reported a decreased plasminogen activator activity in the 
plasma of tumor-bearing patients compared to normal 
subjects (Colombi et al., 1984). Another study reported 
that plasminogen activator was enriched in the tumor cell 
membranes, however serine inhibitors did not abrogate 
collagenolytic activity (Zucker et al., 1985). 
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one of the questions regarding the possible role of 
urokinase in the metastatic process is whether urokinase 
activity is required in the early steps such as 
intravasation or during the later steps such as 
extravasation. Earlier work of Ossowski and Reich (1983) 
showed that the injection of an antibody to urokinase into 
the chick embryo prevented cells, which were placed on the 
chorioallantoic membrane, from metastasizing to the 
embryonic lung. However, if the human HEp2 tumor cells 
were placed directly into a vein, the urokinase antibody 
had no inhibitory effect on lung colonization (Ossowski, 
1988). These results may indicate that urokinase is only 
required for the intravasation step into the blood 
vessels, but not for extravasation out of the blood 
vessels (Ossowski, 1988). 
Contrary to this, several other studies reported 
that an increase in urokinase activity is correlated with 
increased lung colonization following i.v. injection, 
urokinase therefore plays a causal role in the 
extravasation step of the metastatic cascade. Hearing et 
al. (1988) showed that Bl6 cells pretreated with antibody 
to urokinase on their cell surf aces showed decreased 
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numbers of metastases and that pretreatment of Bl6-Fl0 
cells with plasmin, which converts single chain urokinase 
to the more active two chain form of urokinase, increased 
the numbers of metastases in the lung colonization assay. 
very recently, Axelrod et al. (1989) expressed the 
urokinase gene in H-ras-transf ormed NIH3T3 cells by 
transfection of recombinant gene, and found that the 
increase in urokinase gene expression resulted in a large 
increase in pulmonary metastasis following tail vein 
injection in nude mice. Also Brunner et al. (1989) 
reported that mouse bladder carcinoma cells transf ected by 
Ha-ras cells produced a 3-f old increase in urokinase 
activity in cell lysates and 3-fold increase in cell 
surface-associated urokinase activity. This particular 
clone induced a 6-fold increase in lung colonies. 
Urokinase Receptor 
A specific cell surface receptor with high affinity 
for urokinase has been first identified in human blood 
monocytes (Vassalli et al., 1985) and is present on a 
variety of normal cells, such as fibroblasts, endothelial 
cells, granulocytes, spermatozoa, and a number of 
malignant tumor cells (Testa and Quigley, 1988; Stoppelli 
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gt al., 1986; Vasaalli et al., 1985). It has been 
purified from several cell lines (Needham et al., 1987; 
Nielsen et al., 1988; Estreicher et al., 1989). The 
receptor appears to be a 55-60 Kd glycoprotein (Nielsen et 
al., 1988). The number of receptors on cells, such as 
monocytes or fibroblasts is about 105 sites per cell 
(Blasi et al., 1986). The urokinase receptor binds to the 
amino terminal fragment (ATF) of the single chain form of 
prourokinase or to the two chain form of urokinase 
(Stoppelli et al., 1985). More precisely it binds within 
the first 32 residues of the growth factor domain in 
urokinase (Appellal et al., 1987). Therefore, the binding 
of urokinase is completely independent of the catalytic 
domain which is located in carboxyl terminal of the 
urokinase molecule (Stoppelli et al., 1985; Appella et 
al., 1987). The 33 Kd urokinase, generated by plasmin 
from the 54 Kd urokinase, does not bind to the receptor 
(Needham et al., 1987). 
It has been reported by immunofluorescence, 
immunoprecipitation, and surface iodination assays that 
the same cells have both secreted and membrane associated 
urokinase activities (Stoppelli et al., 1986). This 
suggests that prourokinase might be initially secreted 
into the extracellular space with subsequent binding to 
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the specific receptor via an autocrine mechanism. When 
bound to its specific receptor, urokinase is not 
internalized so its enzymatic activity is retained. Mild 
acid treatment releases the receptor bound urokinase from 
the cell surface (Stoppelli et al., 1986). 
The binding of urokinase to its cellular receptor 
is shown to be extremely specific. Any other related 
proteins, such as epidermal growth factor (EGF), factor IX 
and X, tissue PA, plasminogen, and thrombin do not compete 
for binding with the amino terminal fragment (ATF) of 
urokinase or with high molecular weight urokinase (Blasi 
et al., 1986; Blasi, 1988). Urokinase binding also shows 
species specificity (Stoppelli et al., 1986; Estreicher et 
al., 1989). Murine urokinase binds to murine sperm cells 
but not to human cells (Huarte et al., 1987). 
The binding of urokinase to its receptor is shown 
to be increased by epidermal growth factor (EGF) treatment 
of the carcinoma cells (Blasi et al., 1986; Boyd, 1989). 
Phorbol myristate acetate (PMA) has been shown to increase 
urokinase receptor synthesis in a time and concentration 
dependent manner. PMA treatment also caused a decrease in 
affinity of the urokinase receptor, suggesting another way 
of regulating the interaction between urokinase and its 
receptors (Picone et al., 1988). 
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The function of the urokinase receptor has not been 
established, however, possible advantages have been 
suggested. First, since the carboxyl terminal domain 
remains exposed on the cell surface upon receptor binding, 
urokinase binding might stimulate localized proteolytic 
activity (Stoppelli ~al., 1985; Pollanen et al., 1990). 
secondly, the receptor bound enzyme might be protected 
from inactivation by inhibitors. It has been shown that 
plasmin generated from the cell bound plasminogen is less 
susceptible to inhibitors than its fluid phase counterpart 
(Plow et al., 1986). Thirdly, the binding of urokinase to 
the cell surf ace might concentrate other substrates of the 
multistep pathway, and subsequently increase the rate of 
the cascade reaction (Moscatelli and Rifkin, 1988). 
A possible role of urokinase binding to the 
receptor has been shown by several investigators. As 
stated earlier, urokinase has a growth factor domain in 
its amino acid sequence (Verde et al., 1984) which might 
provide the mitogenic activity of urokinase. The binding 
of urokinase to its receptor seems to be necessary for the 
growth stimulation of certain cell lines. It was 
demonstrated that the 54-Kd urokinase which binds to its 
receptors stimulated the growth and proliferation of human 
epidermal cells (Kirchheimer ~al., 1989) and uterine and 
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ovarian cancer cells (Takada and Takada, 1989), whereas 
the 33-Kd urokinase fragment, which lacks the growth 
factor domain and contains only the active-site domain, 
did not stimulate cell proliferation (Kirchheimer et al., 
1989). 
A question regarding the role of urokinase in 
metastasis concerns its possible location of action. 
Recent work has shown that many tumor cells contain 
urokinase receptors on their cell surfaces (Needham et 
al., 1987; Stoppelli et al., 1986). Likewise, an increase 
in cell surf ace urokinase receptor has been correlated 
with an increased metastatic potential (Boyd et al., 
1988). In vivo invasion assays with chick embryo 
chorioallantoic membrane (CAM) showed that the invasive 
ability of human tumor cells was augmented by saturating 
their receptors with exogenous urokinase. The stimulation 
of urokinase production in the absence of binding to cell 
receptors did not enhance invasiveness (Ossowski, 1988). 
Boyd et al. (1988) determined the levels of urokinase and 
its receptor in colon carcinoma cell lines of different 
differentiation degrees, and found aggressive metastatic 
cell lines expressed a higher number of receptors and a 
higher level of secreted endogenous urokinase activity 
than more indolent cell lines. 
Chapter III 
MATERIALS AND METHODS 
cell Culture 
~
The Bl6-Fl and Bl6-Fl0 cells (Fidler, 1975) were 
kindly provided by Dr. I.J. Fidler, M.D. Anderson Medical 
center, University of Texas, Houston, TX. Cells were 
grown in Eagle's minimal essential medium (MEM) 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS) (Flow Laboratory, McLean, VA), 1% MEM nonessential 
amino acids (Gibco Laboratories, Grand Island, NY), 1 rnM 
sodium pyruvate, 1% MEM vitamin solution (Gibco 
Laboratories), 75 units/ml of penicillin and 75 ug/ml of 
streptomycin sulfate (Gibco Laboratories). Cells were 
incubated at 37 C in 5% co2 saturated with water vapor and 
were maintained by changing the medium every three days 
and subculturing at a 1:3 ratio at confluence. For the 
subculture, cells were detached from the flasks by 
incubation with 1 rnM ethylenediamine tetracetic acid 
(EDTA) in phosphate buffered saline (PBS) for several 
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minutes. The total number of viable cells were determined 
by trypan blue exclusion in a hemocytometer (C.A. Hausser 
and son, Philadelphia, PA). 
BSV2-uPA Plasmid Construction 
The plasmid pSV2-uPA containing the human 
preprourokinase plasminogen activator coding sequences in 
the sense direction was made from two plasmids, pSV2-dhfr 
and pRdzbuktt. pSV2-dhfr was purchased from American 
Tissue Culture Center, Rockville, Md. and pRdzbuktt was a 
gift of Dr. Michael E. Reff, Smith Kline & French & Co., 
King of Prussia, PA. The plasmid pRdzbuktt is a mammalian 
expression vector containing the full length cDNA for 
human preprourokinase, Rous sarcoma virus (RSV) long 
terminal repeats (LTR) promoter, a bovine growth hormone 
(BGH) polyadenylation signal, the dihydrofolate reductase 
(dhfr) terminator, the pBR322 origin of replication, and 
an ampicillin resistant gene (Figure 1). pSV2-dhfr is a 
mammalian expression vector containing the dihydrofolate 
reductase (dhfr) gene, a SV40 early and late gene 
promoters, a SV40 polyadenylation signal, the pBR322 
origin of replication, and an ampicillin resistant gene. 
The strategy of plasmid construction, as shown in Figure 
2, was to replace the dihydrofolate reductase (dhfr) gene 
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Figure 1. Structure of the plasmid pRdzbuktt 
The plasmid pRdzbuktt contains the full 
length cDNA for human preprourokinase, Rous sarcoma 
virus (RSV) long terminal repeats (LTR) promoter, a 
bovine growth hormone (BGH) polyadenylation signal, 
the dihydrofolate reductase (dhfr) terminator, the 
pBR322 origin of replication, and an ampicillin 
resistant gene. The human preprourokinase gene can 
be retrieved from the plasmid by digestion with 
HindIII and SacI. The transcription is clockwise in 
the 5' to 3' direction. Restriction enzymes with 
unique recognition sites are shown on the map. 
Rdibuktt 
5267 
Ellzyns that do not cut: _ 
CJHVejle SJ ta J~ If 
CJeava99 SJ e.· Ua.f, 5 
,Afl2 Ap111 .isu2 BH1 BstE2 Cla1 Dra3 EcoRV Esp1 KPn1 Nar1 1111111 Hot1 HsH Rsr2 
Sac2 SfJ1 S..1 Sna81 Spc1 Spl1 Stu1 Tth31 ,Xbu Xlla3 
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Figure 2. construction of human preprourokinase 
expression vector pSV2-uPA containing SV40 early 
gene promoter 
The human 1021 base pair preprourokinase cDNA 
gene (uPA) was obtained by digestion of plasmid 
pRdzbuktt with SacI and HindIII. Plasmid pSV2-dhfr 
was digested with HindIII and BglII to remove the 
dhfr gene. The uPA sequence was ligated to the 
large fragment (4249 base pairs) of the pSV2 plasmid 
to make the pSV2-uPA expression plasmid containing 
human preprourokinase gene in a sense direction with 
respect to the SV40 early gene promoter. 
Transcription is clockwise in the 5' to 3' 
direction. The protein coding sequences are shown 
in hatched area. 
pSV2~ 
dh!r 
PBR32~(1 
on 
SV40 
ori 
SV40-L 
dh!r 
terminator 
SV40-E 
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DNA polymerase I+ dNTPs 
DNA ligase 
pSV2-uPA 
SV40-E 
uPA 
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of pSV2-dhfr with the preprourokinase gene of pRdzbuktt in 
the sense orientation relative to the SV40 early gene 
promoter. In order to remove the dhfr gene from pSV2-
dhfr, the pSV2-dhfr was digested with HindIII and BglII. 
Both cohesive ends were repaired to give blunt ends by 
incubation with 5 units of T4 DNA polymerase I (Boehringer 
Mannheim Biochemicals, Indianapolis, IN) and 0.5 mM of the 
mixture of dATP, dGTP, dCTP, TTP (Sigma Chemical Co.) in 
an assay buffer provided by the manufacturer, at 37°C for 
30 minutes. The repaired DNAs were then treated with 10 
units of alkaline phosphatase from calf intestine 
(Boehringer Mannheim Biochemicals) to prevent self 
ligation, by incubation for 1 hour at 50 C in the assay 
buffer. The repaired DNA fragments were separated by 
electrophoresis in 0.8% agarose gel. The 4249 base pairs 
of large fragment DNA which contains the entire pSV2-dhfr 
sequences, except for the dhfr gene, was eluted from 
agarose gel using the IBI Analytical Electroeluter 
(International Biotechnologies Inc., New Haven, CT). 
To isolate the human preprourokinase cDNA from the 
plasmid pRdzbuktt, the pRdzbuktt was digested with HindIII 
and SacI, blunt ended as described previously for pSV2 
vector, and separated by electrophoresis. The small 
fragment DNA of pRdzbuktt which contains 1021 base pairs 
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corresponding to the preprourokinase coding sequences was 
eluted. The pSV2-vector fragment and human 
preprourokinase fragment, were ligated overnight at room 
temperature by 2 units of T4 DNA ligase (IBI, New Haven, 
CT) in the assay buffer provided by the manufacturer. The 
ligated DNA was then transformed in E-coli strain HBlOl. 
prior to transformation, the E-coli was cultured in SOB 
medium (2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgC1 2 , 10 mM Mgso4 ), resuspended 
in RFl buffer (lOOmM RbCl, 50 mM MnC1 2 , 30 mM potassium 
acetate, lOmM CaC1 2 .2H2o and 15% glycerol), then in RF2 
buffer (10 mM MOPS, 10 mM RbCl, 75 mM CaC1 2 .2H2 , 15% 
glycerol) to improve transformation efficiency (Hanahan, 
1983). Ampicillin resistant clones were selected and 
grown in LB medium with 50 ug/ml of ampicillin. 
Plasmid DNAs of selected clones were screened for 
the insertion of the preprourokinase gene by restriction 
endonuclease digestion with BglII and were rescreened for 
the pSV2-uPA in the sense orientation by restriction 
endonuclease digestions with BamHI, PstI, and PvuII. The 
clone with the correct digestion fragments for pSV2-uPA 
were amplified in the presence of chloroamphenicol (170 
ug/ml). The plasmid DNA from the selected clone was 
prepared in large scale by the lysis of the E-coli cell 
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wall with 0.2 N NaOH/1% SDS and plasmid DNA extraction 
with isopropanol. The prepared DNA was purified by 
centrifugation to equilibrium in cesium chloride-ethium 
bromide density gradient (Maniatis et al., 1982) for 
transfection. The plasmid structure and the restriction 
digestion map of the constructed pSV2-uPA is shown in 
Figure 3. The final plasmid structure was confirmed by 
additional restriction endonuclease digestions with BamHI, 
PvuII, BglI, EcoRI, and Pstl and a double digestion with 
BglII and HpaI. 
pCLH3AXBPV-uPA Plasmid Construction 
The plasmid pCLH3AXBPV-uPA containing the human 
preprourokinase plasminogen activator gene in the sense 
direction was similarly prepared from pRdzbuktt and 
pCLH3AXBPV as described for pSV2-uPA. The plasmid 
pCLH3AXBPV, obtained from Dr. Gordon (Integrated Genetics, 
Framingham, MA) (Reddy et al., 1987), contains the bovine 
papilloma virus-1 (BPV-1) genome, mouse metallothionein 
(MT-1) promoter, a SV40 polyadenylation signal, the pML-1 
(a derivative of pBR322 origin of replication), and an 
ampicillin resistant gene. The structure of the plasmid 
pCLH3AXBPV is shown in Figure 4. The pCLH3AXBPV was 
linerized by restriction endonuclease digestion with XhoI. 
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Figure 3. structure of the plasmid pSV2-uPA 
The plasmid pSV2-uPA contains the full length 
cDNA for human preprourokinase in the sense 
orientation, SV40 early and late gene promoters, a 
SV40 polyadenylation signal, the pBR322 origin of 
replication, and an ampicillin resistant gene. The 
SV40 early promoter directs the expression of the 
inserted human preprourokinase gene. The 
transcription is clockwise in the 5' to 3' 
direction. The outside plasmid circle, 
corresponding to the inner circle, shows several 
restriction enzymes used to verify the constructed 
pSV2-uPA structure. 
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Figure 4. Structure of the plasmid pCLH3AXBPV 
The plasmid pCLH3AXBPV contains the bovine 
papilloma virus-1 (BPV-1) genome, the mouse 
metallotheionine (MT-1) promoter, a SV40 
polyadenylation signal, a derivative of the pBR322 
origin of replication (pML-1), and an ampicillin 
resistant gene. The plasmid was linerized by the 
restriction endonuclease digestion with XhoI to 
insert human preprourokinase gene. Several 
restriction enzymes used to verify the plasmid 
structure are shown on the map. 
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The pRdzbuktt was digested with HindIII and SacI and the 
human preprourokinase cDNA was separated by 
electrophoresis and eluted from the agarose gel. The 
pCLH3AXBPV vector and the human preprourokinase fragment 
were repaired to blunt ends with T4 DNA polymerase and a 
mixture of four deoxynucleotide triphosphates and the two 
ends were ligated. The construction scheme is shown in 
Figure 5. The ligated DNA was transformed in E-coli and 
the ampicillin resistant clones were selected. The 
selected clones were screened for pCLH3AXBPV-uPA by the 
restriction endonuclease digestions with HpaI, HindIII, 
and EcoRI. The final plasmid construction was confirmed 
by the additional restriction digestions with BamHI, 
PvuII, and a double digestion with PvuI and PstI. The 
plasmid structure and the restriction digestion map of the 
constructed pCLH3AXBPV-uPA is shown in Figure 6. 
pSV2-ASuPA Antisense Plasmid Construction 
The plasmid pSV2-ASuPA containing the 5'end 265-
base-pair of preprourokinase sequence in the antisense 
direction was similarly prepared from pSV2-dhfr and 
pRdzbuktt as shown in Figure 7. The pSV2-dhfr was 
digested with HindIII and BglII and the vector fragment of 
pSV2 was separated by electrophoresis and eluted from the 
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Figure 5. Construction of human preprourokinase 
expression vector pCIJl3AXBPV-uPA containing bovine 
papilloma virus-1 (BPV-1) and metallothionein-1 (MT-
1) promoter 
The human 1021 base pair preprourokinase cDNA 
gene (uPA) was obtained by digestion of plasmid 
pRdzbuktt with Sacl and HindIII. The plasmid 
pCLH3AXBPV was linerized by the digestion with XhoI. 
The uPA sequence was ligated to the linear 
pCLH3AXBPV to make the pCLH3AXBPV-uPA expression 
plasmid containing human preprourokinase gene in a 
sense direction with respect to the MT-1 promoter. 
Transcription is clockwise in the 5' to 3' 
direction. The hatched area represents the 
preprourokinase coding sequences. 
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Figure 6. Structure of the plasmid pCLH3AXBPV-uPA 
The structure of plasmid pCLH3AXBPV-uPA is 
identical with that of pCLH3AXBPV except the full 
length cDNA for human preprourokinase was inserted 
in the sense orientation at XhoI site. The MT-1 
promoter directs the expression of inserted human 
preprourokinase gene. The transcription is 
clockwise in the 5' to 3' direction. The outside 
plasmid circle, corresponding to the inner circle, 
shows several restriction enzymes used to verify the 
constructed pCLH3AXBPV-uPA structure. 
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Figure 7. construction of human urokinase antisense 
gene expression vector pSV2-ASuPA. 
The human 5'end 265 base pairs of 
preprourokinase cDNA was obtained by digestion of 
plasmid pRdzbuktt with HindIII and NcoI. Plasmid 
pSV2-dhfr was digested with HindIII and BglII and 
the large fragment was purified. Two fragments were 
ligated at HindIII sites in an antisense direction. 
The cohesive ends of ligated DNA, NcoI and ~II 
sites, were blunted by T4 DNA polymerase followed by 
blunt ligation. Transcription is clockwise in the 
5' to 3' direction. 
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agarose gel. The pRdzbuktt was digested with HindIII and 
H9.QI and 265-base-pair fragment containing the human 
preprourokinase sequence was purified and eluted from the 
agarose gel. Two purified fragments were ligated at the 
HindIII site which resulted in a 265-base-pair fragment 
~ 
attached to pSV2-dhfr digest in an antisense orientation 
with respect to the SV40 early gene promoter. The 
cohesive ends of the ligated DNA were blunted with T4 DNA 
polymerase and a mixture of four deoxynucleoside 
triphosphates, ligated, and then transformed in HBlOl. 
The selected ampicillin resistant clones were analyzed for 
the correct orientation by restriction endonuclease 
digestions with BglI, PstI, and PvuII. The final pSV2-
ASuPA plasmid construction was confirmed by additional 
restriction digestions with BglI and PstI and double 
digestions with PvuII-BamHI, BamHI-EcoRI, EcoRI-HpaI and 
HpaI-PvuI. The plasmid structure and the restriction 
endonuclease digestion map of the constructed pSV2-ASuPA 
structure is shown in Figure 8. 
DNA Transf ection 
DNA transf ection was performed by the calcium-
phosphate coprecipitation technique of Graham and van der 
Eb (1973), with modifications. Twenty-four hours before 
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Figure 8. Structure of the plasmid pSV2-ASuPA 
The plasmid pSV2-ASuPA contains the HindIII 
and NcoI digestion fragment of human preprourokinase 
in the antisense orientation with respect to the 
SV40 early gene promoter, the SV40 early and late 
gene promoters, a SV40 polyadenylation signal, the 
pBR322 origin of replication, and an ampicillin 
resistant gene. The SV40 early promoter directs the 
expression of the inserted human preprourokinase 
antisense gene. The transcription is clockwise in 
the 5' to 3' direction. The outside plasmid circle, 
corresponding to the inner circle, shows several 
restriction enzymes used to verify the constructed 
pSV2-ASuPA structure. 
pSV2-ASuPA 
ASuPA 
Start 
ECoRI 
Pstl 
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the transfection, approximately 5 x 105 cells were seeded 
in 100 mm Petri dishes containing Eagle's MEM and 10% 
heat-inactivated FBS. The DNA used for transfection was 
purified by alkaline lysis extraction followed by CsCl 
density gradient centrifugation, and then dialyzed against 
TE-buffer (Maniatis et al., 1982). The DNA used for the 
transfection was in the form of closed circular plasmid 
DNA. Bl6-Fl cells were cotransfected with 10 ug of 
constructed plasmid containing the human preprourokinase 
gene (pSV2-uPA, pCLH3AXBPV-uPA or pRdzbuktt) and 1 ug of 
pSV2-neo (American Type Culture Collection). Bl6-Fl0 
cells were cotransfected with 10 ug of pSV2-ASuPA and 1 ug 
of pSV2-neo. For the control, 1 ug of pSV2-neo alone was 
used. The CaP04/DNA mixture was prepared by combining DNA 
with 2 M CaC1 2 in HBSP buffer (1.5 mM Na 2HP04 , 10 mM KCl, 
280 mM NaCl, 12 mM glucose, 50 mM HEPES, pH 7.05) and was 
allowed to form a precipitate for 30 minutes at room 
temperature without any disturbance. All the solutions 
except DNA were kept sterile prior to transfection. The 
CaP04/DNA precipitate was then slowly added to the cells 
• • • 0 in a dropwise manner and the cells were incubated at 37 c 
in 5% co2 saturated with water vapor for 16 hours. At the 
end of the transfection period, the cells were shocked 
with 15% sterile glycerol in HBSP buffer for 3 minutes at 
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37°c. The cells were then allowed to recover in MEM 
supplemented with 10% heat inactivated FBS for 24 hours at 
37°c. The cells were subcultured at a 1:3 ratio and 
transferred to MEM with 10% heat inactivated FBS 
containing 1.5 mg/ml Geneticin (G-418) (Gibco 
Laboratories, Grand Island, NY). The cells were provided 
with fresh MEM with 10% heat inactivated FBS containing 
Geneticin every three days. Two weeks after the 
initiation of Geneticin treatment, the transfected cells 
were monitored every day and about four weeks later the 
surviving cell colonies were further processed. 
Fibrin Overlay Assay for Plasminogen Activator 
The transient expression of the urokinase gene of 
the transfected cells were assayed by the fibrin overlay 
assay for plasminogen activator with minor modifications 
(Kenten et al., 1986). Two days after the transfection, 
the cells were detached and collected from the petri 
dishes by incubation with 1 mM EDTA in PBS and then washed 
twice in serum-free MEM. The cell suspension solution 
(70% MEM supplemented with 10% heat inactivated FBS, 30% 
Hank's balanced salt buffer (Gibco Laboratories), 
supplemented with 2.5% low-gelling-temperature agarose) 
(type VII, A-4018, Sigma Chemical Co.) was prepared and 
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incubated at 42°C until the agarose was dissolved. To the 
9 ml of cell suspension solution, 0.7 units of thrombin 
(from bovine plasma, T-6759, 276 units/ml, Sigma Chemical 
co.) and 5 x 104 cells were added and rapidly mixed by 
inverting the test tube. Then 1.5 ml of MEM supplemented 
with 10% heat inactivated FBS containing 30 mg/ml 
fibrinogen (from bovine blood, F-4753, Sigma Chemical Co.) 
was rapidly added and the mixture was poured immediately 
into 100-mm petri dish. The dishes were incubated at 37°C 
in 5% co2 saturated with water vapor for 24 hr. After the 
incubation, the number of clearing zones which represent 
the presence of the cells that produce urokinase were 
counted. As a reference, C127 cells obtained from ATCC 
were transfected with pCLH3AXBPV-uPA and assayed in the 
same manner to detect urokinase activity in the 
transfected cells as documented by Reddy et al. (1987). 
For the positive control, 10 ul of human urokinase (High 
molecular weight urokinase, #124, 80,000 IU/mg, from 
American Diagnostica Inc., New York, NY) solution (3.6 
ug/ml) was added dropwise on the agarose fibrin plate. 
Immunoblot Detection of Hum.an urokinase Production by_ 
Transf ected Cell Colonies 
The surviving colonies of transfected cells were 
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analyzed for the production of human urokinase by a filter 
immunoblot assay (McCracken and Brown, 1984) with 
polyclonal antibody to high molecular weight human 
urokinase (American Diagnostica, New Haven, CN, Antibody 
#389). This assay was not used quantitatively, but only 
used to verify the presence of urokinase production in the 
colonies. Prior to the assay, the medium was removed from 
the petri dish containing transf ected Bl6-Fl or Bl6-Fl0 
colonies. The cells were washed twice with serum free 
medium (SFM), then 2.5 ml of SFM was added to the cell. 
An autoclaved disc of teflon mesh (Spectrum Medical 
Industries Inc., Los Angeles, CA) was placed over the cell 
colonies and a sterile notched nitrocellulose membrane 
filter disc (Millipore, Bedford, MA) was laid over the 
teflon mesh. The cell colonies were then incubated for 7 
to 8 hours at 37°C. After the incubation, the filter and 
mesh were removed and the cells were re-fed with MEM 
containing 10% heat inactivated FBS with Geneticin until 
colony transfer. The filters were soaked in Denhardt's 
solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% 
ovalbumin in 150 mM NaCl, 10 mM sodium phosphate, pH 7.4) 
0 for 16 hours at 4 c to block any non-specific binding 
sites, washed with PBS-Tween (PBS containing 0.05% Tween-
20), and then incubated with 1:500 diluted rabbit 
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polyclonal antibody to human urokinase (American 
oiagnostica Inc., New York, NY, antibody #389) in PBS-
Tween containing 0.1% ovalbumin for 2 hours at room 
temperature. The filters were subsequently washed and 
incubated with 1:300 diluted goat antirabbit IgG 
conjugated with alkaline phosphatase (Biorad, Richmond, 
CA) in PBS-Tween for 1 hour at room temperature. After 
the second antibody treatment, filters were again washed 
and incubated with BCIP/NBT (5-bromo-4-chloro-3-indoyl 
phosphate/nitroblue tetrazolium) solution (Biorad) in 
carbonate buffer (0.1 M NaHC0 3 , 1.0 mM MgC1 2 , pH 9.8) for 
alkaline phosphatase color development. After the filters 
were processed, photocopies and transparencies were made. 
Ouantif ication of Urokinase Production .Qy ELISA 
The transparencies made from the immunoblot filters 
were aligned with original culture dishes and twenty 
positive colonies, dark purple spots on the filters, were 
selected. These were transferred to separate petri 
dishes. The cells in each colony were picked up using 
yellow Pipetman tips after they were released from the 
Petri dishes by scraping under the microscope in a sterile 
hood. They were allowed to proliferate in MEM 
supplemented with 10% heat inactivated FBS. In order to 
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select the colonies that produce the highest amount of 
urokinase, the secretion of urokinase from each colony was 
quantitated by IMUCLONE Urokinase Plasminogen Activator 
ELISA Kit (American Diagnostica Inc., New York, NY). This 
ELISA Kit detects both single and two-chain urokinase 
(IMMUCLONE uPA ELISA Kit manual, American Diagnostica 
Inc.). Forty hours prior to ELISA, 2.5 x 104 cells were 
seeded in 25 mm petri dishes in serum free MEM and 
0 
incubated at 37 C. A 100 ul aliquot of conditioned medium 
was removed from each colony and added to the ELISA plate 
wells coated with murine monoclonal antibody to human 
urokinase (high and low molecular weight urokinase). The 
• • 0 • plates were incubated for 90 minutes at 37 C in the buffer 
provided by the manufacturer. The wells were then washed 
and incubated with rabbit anti-human urokinase conjugated 
with horseradish peroxidase at 37°C for 1 hour. After 
incubation with the second antibody, the substrate was 
added for peroxidase color development and incubated for 
30 minutes at room temperature. After the final 
incubation, the reaction was stopped with solution 
provided and absorbances were read at 405 nm in an ELISA 
microplate spectrometer {Minireader II, Dynatach Labs, 
Inc., Alexandria, VA). Each colony was tested in 
triplicate and three separate experiments were performed. 
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Sf>Uthern Blot Hybridization Analysis of B16-F1 and B16-F1 
p$V2-uPA transf ected cells 
The genomic DNAs of Bl6-Fl cells, pSV2-neo 
transfected cells, and clone 7 (C7) of pSV2-uPA 
transfected Bl6-Fl cells were isolated by standard methods 
(Davis et al., 1986). The genomic DNAs of Bl6-Fl and 
transfected Bl6-Fl cells and the pSV2-uPA plasmid were 
digested with BamHI or PstI and electrophoresed overnight 
on a 0.8% agarose gel. The DNAs were Southern blotted to 
nitrocellulose filter (Trans-Blot Transfer Medium, Bio-
Rad) by the capillary transfer method. For the cDNA 
probe, pSV2-uPA was double digested with HpaI and PstI and 
the DNA fragment containing the preprourokinase sequence 
was purified by electrophoresis and DNA electroelution. 
The probe was labeled with 32 P-dCTP by nick translation 
(Nick Translation System, BRL, Life Technologies, Inc., 
Gaithersburg, MD). Briefly, the probe DNA was added to 
the reaction mixture containing dATP, dGTP, dTTP, and 32P-
dCTP (ICN Biomedicals, Inc., Irvine, CA) and nick 
translated by incubation with 1 U of DNA polymerase I and 
0 100 pg of DNase I at 15 c for 60 minutes. The nick-
translated CTP was separated from unincorporated 32P-
labeled CTP by NICK-Column (Pharmacia Fine Chemicals, 
Uuppsala, Sweden) which contains Sephadex G-50 DNA Grade. 
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The nitrocellulose filter was hybridized with 32P-labeled 
probe in hybridization solution containing 5X Denhardt's 
(lX Denhardt's = 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 
0.02% BSA), 1% SDS, 100 ng/ml denatured salmon sperm DNA, 
b 0 . 1 M NaCl/10 mM Na 3Po4 uffer, pH 6.5, at 65 c overnight. 
The filter was then washed four times for 30 minutes each 
wash with 0.2X SSC (lX SSC = 0.15 M NaCl, 0.015 M sodium 
0 
citrate, pH 7.0) containing 0.5% SDS, at 65 c and exposed 
to X-ray film (Kodak X-OMAT AR Diagnostic Film, Eastman 
Kodak Co., Rochester, NY) at -7o 0 c with an intensifying 
screen (Dupont Cronex Lighting Plus GJ 220004, Dupont Co., 
Wilmington, DE). To estimate the relative amounts of 
hybridization, the autoradiographs were scanned by a Gel 
Scan densitometer equipped with a Gilford Response UV-VIS 
Spectrometer (Gilford Systems, Oberline, OH). 
Southern Blot Hybridization Analysis of B16-F1 and Bl6-Fl 
pSV2-neo and pRdzbuktt transf ected cells to detect pSV2-
neo incorporation 
The genomic DNAs of Bl6-Fl cells and pSV2-neo 
transfected cells, pSV2-neo and pRdzbuktt cotransfected 
cells were similarly isolated. The prepared genomic DNAs 
and the plasmid pSV2-neo were digested with HindIII or 
double digested with HindIII and BamHI or HindIII and 
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£§.t_l, electrophoresed overnight on a 0.8% agarose gel, and 
blotted to nitrocellulose filter. For the cDNA probe, 
psv2-neo was digested with HindIII and Pstl and the DNA 
fragment containing the neo gene was used. The probe was 
labeled with 32P-dCTP by nick translation. The 
nitrocellulose filter was similarly hybridized with the 
probe and exposed to X-ray film. 
southern Blot Hybridization Analysis of B16-F1 and B16-F1 
pRdzbuktt transf ected cells to detect pRdzbuktt 
incorporation 
To detect the pRdzbuktt incorporation, the plasmid 
pRdzbuktt and the isolated cell DNAs were digested with 
HindIII or double digested with HindIII and Sac! or 
HindIII and Pstl and were separated by electrophoresis. 
DNAs were Southern blotted to nitrocellulose filter. For 
the cDNA probe, pRdzbuktt was double digested with Sac! 
and HindIII and the fragment containing the human 
preprourokinase gene was used for the hybridization. The 
probe was labeled with 32P-dCTP by nick translation. The 
nitrocellulose filter was similarly hybridized with the 
probe and exposed to X-ray film. 
~outhern Blot Hybridization Analysis of B16-F10 and B16-
F10 Antisense Transf ected Cells 
~
The genomic DNAs of B16-Fl0 cells, pSV2-neo 
transfected cells, and antisense clones 10 (AClO) and 8 
(AC8) of pSV2-ASuPA transfected Bl6-Fl cells were 
similarly isolated, digested with PstI, and 
electrophoresed on a 0.8% agarose gel. The DNAs were 
southern blotted to nitrocellulose filter. For the cDNA 
probe, pSV2-ASuPA double digested with HpaI and PstI and 
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the DNA fragment containing the preprourokinase sequence 
was purified. The probe was labeled with 32P-dCTP by nick 
translation. The nitrocellulose filter was similarly 
hybridized with the probe and exposed to X-ray film. 
Northern Blot Hybridization Analysis of B16-Fl and B16-Fl 
Cells Transfected with pSV2-uPA 
The cytoplasmic RNAs of Bl6-Fl, Bl6-Fl pSV2-neo 
transfected cells, and pSV2-uPA transfected cells (clone 7 
and 10) were extracted by a standard method (Ausubel et 
al., 1988). Briefly, the cells were washed and collected 
in cold PBS and lysed in ice-cold lysis buffer (50 mM 
Tris-Cl, pH 8.0, 100 mM NaCl, 5 mM MgC1 2 , 0.5% Nonidet P-
40 in DEPC-treated water). The contaminating proteins 
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were denatured with proteinase K and the RNA was purified 
bY phenol extraction. The prepared RNAs were separated 
overnight by electrophoresis in 1% agarose/0.02% 
formaldehyde gel in MOPS buffer (0.2 M MOPS, 0.05 M sodium 
acetate, 0.01 M EDTA). The RNAs were transferred to 
Nytran Nylon Membrane (Schleicher & Schuell, Keene, NH) by 
the capillary transfer method, and immobilized by a 
covalent bond using the UV crosslinking technique (UV 
stratalinker 1800, Stratagene, La Jolla, CA). For the 
cDNA probe, pSV2-uPA was double digested with BamHI and 
PstI and the DNA fragment containing preprourokinase 
sequence was labeled with 32P-dCTP by nick translation. 
The Nytran filter was hybridized with 32P-labeled probe in 
hybridization solution containing 50% formamide, 2.5X 
Denhardt's reagent, 200 ug/ml of denatured salmon sperm 
DNA, 0.5% SOS, and 5X SSPE (lX SSPE = 0.18 M NaCl/10 mM 
NaPo4 , pH 7.7/1 mM EDTA) at 42°C overnight. The filter 
was washed twice in 6X SSPE and 0.5% SOS at room 
0 temperature, twice in lX SSPE and 0.5% SOS at 37 C, and 
once in lX SSPE and 0.5% SOS at 60°C. The filter was 
0 
exposed to X-ray film at -70 C. To rehybridize the blot, 
the pSV2-uPA probe was removed by boiling the filter for 
20 minutes in O.OlX SSPE/0.5% SOS and rinsing twice in 2X 
SSPE. For the internal standard control, the stripped 
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filter was similarly hybridized with 32P-labeled 
Drosophila actin (Fryberg et al., 1983) obtained from Dr. 
Mark Kelley (Loyola University Medical Center) and exposed 
to X-ray film. 
Assay of the Binding of Human Urokinase to the Human PC3-
Met Cell Line and the Murine B16-Fl Cell line 
The binding of human urokinase to B16-Fl or PC3-Met 
cells (obtained from Dr. James Kozlowski, Northwestern 
University, Chicago, IL) was determined by the procedure 
of Stoppelli et al. (1985), with modifications. For B16-
Fl cells, 5 x 105 cells were seeded in 2 ml of MEM 
supplemented with 10% heat-inactivated FBS in 6-well plate 
(Elkay Products, Inc., Shrewbury, MA) and incubated at 37° 
C in 5% co2 for 24 hours prior to the assay. For PC3-Met 
cells (Kozlowski et al., 1984), 2.5 x 105 cells were 
similarly seeded in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% heat-inactivated FBS. The 
cells were gently washed twice with PBS containing 1 mg/ml 
of bovine serum albumin (BSA). In order to unmask 
urokinase receptors on the cell surface, the cells were 
incubated for 3 minutes at room temperature in 50 mM 
glycine-HCl buffer, pH 3.0, containing 0.1 M NaCl, and 
quickly neutralized with 0.5 M HEPES buffer, pH 7.5, 
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containing 0.1 M NaCl (Stoppelli et al., 1986). The acid 
treated cells appeared undamaged and bound to the plates. 
The cells were then washed twice with serum-free MEM 
containing 20 mM HEPES, pH 7.5, and 1 mg/ml of BSA and 
incubated for 1 hour at 37°C in the same buffer containing 
4x10 4 cpm of 125I labeled human urokinase (see below) to 
which different concentrations of unlabeled human 
urokinase (American Diagnostica Inc., high molecular 
weight, #124, 80,000 IU/mg) were added. After incubation, 
the cells were washed four times with PBS containing 1 
mg/ml of BSA and lysed by incubation in 20 mM HEPES 
buffer, pH 7.5, with 1% Triton X-100 and 10% glycerol for 
30 minutes at room temperature. The lysed cells were 
counted in a gamma-ray counter (1191 Gamma Trac, Tm 
Analytic, Inc., Elk Grove Village, IL). Nonspecific 
binding was determined in the presence of excess (50 nM) 
unlabeled human urokinase and subtracted from the each 
experimental value. Each experimental concentration was 
performed in triplicate and the results were plotted as 
the mean cpm ± standard deviation. 
125x Labeling of Human Urokinase 
Three Iodo-Beads (Pierce Chemical Co., Rockford, 
IL) and 1 mCi of Na125I in NaOH (IMS300, Amersham Corp., 
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Arlington Heights, IL) were incubated in 0.05 M KHP04 , 0.2 
M NaCl, pH 7.5, at room temperature for 5 minutes with 
gentle shaking. Human urokinase (High molecular weight 
urokinase, #124, 80,000 IU/mg from American Diagnostica 
Inc., New York, NY), 50 ug, was added to the iodination 
mixture and incubated at room temperature for 20 minutes 
with gentle shaking. The 125I human urokinase was 
separated from free Na125I by gel filtration through a 9 
ml Bio-Gel P-6 column (100-200 Mesh, Bio-Rad Laboratories) 
which was presaturated by washing with five column volumes 
of the above buff er containing 2 mg/ml of BSA. The 
urokinase 125I fractions were combined and dialyzed 
extensively against 0.05 M KHP04 , 0.2 M NaCl buffer with 1 
mM KI overnight and then against 0.05 M KHP04 , 0.2 M NaCl 
buffer. The amount of protein was determined by the BIO-
RAD Protein Assay Kit (Bio-Rad Laboratories) according to 
the manufacturer's instruction. 
Determination of Glycosylation of Human Urokinase 
A Concanavalin A affinity chromatography column was 
used to determine if human urokinase produced by 
transfected murine cells was glycosylated. Con A-
Sepharose (Pharmacia Fine Chemicals, Uuppsala, Sweden) (1 
ml) was packed in a blue Eppendorf pipette tip and washed 
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with 50 mM Tris buffer, pH 7.5. The resin was further 
prepared by washing with buffer containing 100 mM sodium 
acetate, 1 mM NaCl, 10 mM cacl2 , 10 mM MgC1 2 , pH 6.0. 
conditioned medium, prepared by incubating 5x105 cells of 
clone 7 of pSV2-uPA transf ected Bl6-Fl in 2 ml of serum 
0 free MEM in a 6-well plate for 40 hours at 37 c, was 
collected and applied to the ConA sepharose column. The 
column was washed with four column volumes of 50 mM Tris 
buffer and then with the same buffer containing 0.5 M 
alpha-methyl-D-mannoside (Sigma Chemical Co.) to elute the 
glycosylated protein from the resin. Fractions of 400 ul 
were collected and assayed for human urokinase by the 
IMUCLONE Urokinase Plasminogen Activator ELISA Kit 
(American Diagnostica, Inc.) using a monoclonal antibody 
to human urokinase, as described above. 
Collection of Conditioned Medium for Quantification of 
Urokinase Activity Secreted by. Cultured Cells 
The cells were plated in 6-well cell culture plates 
at a concentration of 2 x 10 5 cells per well in MEM 
supplemented with 10% heat-inactivated FBS and incubated 
overnight at 37°C in a 5% co2 atmosphere. The cells were 
rinsed twice with serum free medium (SFM) and incubated 
for 24 hours in SFM at 37°C in a 5% co2 atmosphere. The 
cell conditioned media was collected and the cells were 
harvested and counted. 
v..uorogenic Substrate Assay for Plasminogen Activator 
A._ctivity 
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Plasminogen activator activity was measured by 
fluorescence spectroscopy as described by O'Donnell-Tormey 
and Quigley (1983). Cells to be assayed were collected by 
incubation with 0.25% of trypsin (Worthington Biochemical 
corp., Freehold, NJ) in PBS containing 1 mM EDTA for few 
seconds. Cells were washed with PBS three times and 
resuspended in HEPES buffer (5% dimethyl sulfoxide in 0.05 
M HEPES, pH 7.4) at the concentration of 1 x 106 cells/ml. 
Cell suspension solution (400 ul) was mixed with 170 ul of 
HEPES buffer, 30 ul of fluorogenic substrate for 
plasminogen activator, methoxysuccinyl-L-Gly-L-Gly-L-Arg-
7-amino-4-methylcoumarin HCl (Bachem Fine Chemicals, Inc., 
Torrance, Calif.) (final concentration of 10 mM). The 
release of 7-amino-4-methylcoumarin (AMC) from the 
substrate was measured in a Perkin-Elmer MPF-44B 
Fluorescence Spectrophotometer at an excitation wave 
length of 380 nm and an emission wave length of 460 nm. 
The linear release of AMC was recorded for 5 minutes and 
the slope of the linear curve was measured. To calibrate 
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the instrument, 7-amino-4-methyl coumarine (Sigma Chemical 
co.) was used as a standard. For the standard curve, 
different dilutions of human urokinase (High molecular 
weight urokinase, #124, from American Diagnostica Inc., 
New York, NY) were used instead of cells. 
chromogenic Substrate Assay for Plasminogen Activator 
Activity 
Plasminogen activator activity was measured 
spectroscopically using a chromogenic substrate for 
plasmin as previously described by Whur et al. (1980). 
Ten ul of cell conditioned media was added to 100 ul of 
100 mM Tris buffer, pH 8.1, containing 5 ug of plasminogen 
(Sigma Chemical Co.), 15 ug of S-2251 (H-D-Val-Leu-Lys-p-
nitroanilide, KabiVitrum, Stockholm, Sweden), and 0.1% 
Triton X-100 in 96-well plates. Plasminogen was treated, 
prior to use, to inhibit any active plasmin activity by 
incubating plasminogen with diisopropylfluorophosphate 
(DFP) at 25 mM in 50 mM Tris buffer, pH 8.1, at 37°C for 1 
hour and then extensively dialyzing against the same 
buffer. Plasmin activity was measured with DFP-treated 
plasminogen to ensure plasmin activity was no longer 
detected by the same assay. The plates were incubated for 
16 hours at 37°C in a 5% co2 atmosphere. After incubation, 
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the p-nitroaniline absorbances, corresponding to substrate 
hydrolysis by plasmin, were read at 405 nm in a 
spectrometer (Minireader II, Dynatech Labs, Inc., 
Alexandria, VA). 
To test the stability of urokinase gene expression 
in the transfected cells in a longer period of time, one 
of the flask of Clone 7 of pSV2-uPA transfected Bl6-Fl 
cells were passaged more than 20 times. The conditioned 
medium was collected from that particular flask and 
assayed for the plasminogen activator activity by the same 
method. Determination of the standard curve of 
plasminogen activator activity and nonspecific activity 
were included in each assay. 
The nonspecific activity was determined in the 
absence of cell conditioned medium and subtracted from 
each experimental value. For the background activity, 
reaction buff er was used instead of plasminogen for the 
assay. Each experiment was performed in triplicate and 
five separate experiments were assayed. Plasminogen 
activator activity was expressed in pg secreted in the 
conditioned medium per cell per hour. 
1251-fibrin Plate Assay for Plasminogen Activator Activity 
The procedure was similar to that described 
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previously by Strickland and Beers (1976). Bovine 
fibrinogen (Sigma Chemical Co.) was iodinated with Nal251 
by the same procedure as described above for the 1 251 
labeling of human urokinase. The specific radioactivity 
of the fibrinogen was adjusted to 15,000 cpm/ug of 
fibrinogen by the addition of unlabeled fibrinogen. To 
each well of a 24-well plate (Gibco Laboratories), 250 ul 
of 1251-fibrinogen in 50 mM Tris buffer, pH 8.1 (50,000 
. • 0 
cpm per well) was added and dried in a 37 C dry oven for 
two days. Prior to use, wells were incubated with 500 ul 
of MEM supplemented with 5% plasminogen-depleted FBS at 37° 
c in a 5% co2 atmosphere to convert fibrinogen to fibrin. 
Plasminogen-depleted FBS was prepared by repeated 
0 incubation of FBS at 56 C for 45 minutes. Wells were 
washed three times with 50 mM Tris buffer, pH 8.1 and 
incubated for 2 hours with 100 ul of cell conditioned 
medium, 75 ug of BSA and 10 ug of DFP treated plasminogen 
0 (Sigma Chemical Co.) in the 300 ul of same buffer at 37 C 
in a 5% co2 atmosphere. At the end of the incubation 
period, a 100 ul aliquot of supernatant was taken from 
each well and counted in a gamma-counter. Nonspecific 
activity was determined in the absence of conditioned 
medium and subtracted from each experimental value. For 
the background activity, reaction buffer was used instead 
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of plasminogen for the assay. A standard curve was 
included in every assay. Each experiment was performed in 
triplicate and five separate experiments were assayed. 
p1asminogen activator activity was expressed in pg 
secreted in the conditioned medium per cell per hour. 
Murine Lung Colonization Assay 
The murine Bl6-Fl or Bl6-Fl0 melanoma lung assay 
was performed in a similar manner as previously described 
by Fidler (1978). Transfected Bl6-Fl or Bl6-Fl0 cells 
were grown to semi-confluency (80-90%) in MEM supplemented 
with 10% heat inactivated FBS and harvested by the 
addition of 1 ml of 1 mM EDTA in PBS, pH 7.4 at 37°C for 1 
minute. MEM supplemented with 10% heat inactivated FBS 
was added, centrifuged, and resuspended in PBS. The cells 
were counted using a Coulter Counter (Coulter Electronics, 
Inc., Hialeah, FL) and diluted to 5xlo5 cells/ml. The 
viability of the cells was determined by counting trypan 
blue exclusion. The cells were maintained on ice prior to 
injection. A total of 26 female C57BL/6 mice, 6-8 weeks 
old (Harlan Laboratories, Indianapolis, IN) were equally 
divided into control and experimental groups. Mice were 
housed in the Loyola Medical Center Animal Research 
Facility for one week prior to use. A 0.2 ml aliquot of 
cell suspension (100,000 cells per mouse) were slowly 
injected into the lateral tail vein of each mouse 
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while immobilized in a mouse vice. The injection schedule 
alternated between mice in the control group and mice in 
the experimental group to minimize the variance in time. 
The animals were sacrificed 17 days after the injection of 
transfected cells by administering an overdose of ether. 
The lungs were removed and fixed in Bouin's solution 
(0.75% picric acid, 25% formaldehyde, 5% glacial acetic 
acid) overnight. The number of surface tumor colonies, 
easily visible as black or white nodules on the yellow 
Bouin's background, were counted under a dissecting 
microscope. 
Spontaneous Metastasis Assay 
The assay of spontaneous metastasis from a foot pad 
tumor was carried out by the procedure of Fidler (1986), 
with minor modifications. Cells were grown to semi-
confluency in MEM supplemented with 10% heat inactivated 
FBS, harvested, and tested for viability, and counted as 
described above. Female C57BL/6 mice, 6-8 weeks old 
(Harlan Laboratories) were housed in the Loyola Medical 
Center Animal Care Facility for one week prior to use. 
Mice were lightly anesthetized with ether and injected 
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subcutaneously into a posterior footpad with 10 5 cells of 
clone 7 of B16-Fl transf ected cells for experimental 
animals or pSV2-neo transfected cells for a control. The 
cells for injection were suspended in 0.05 ml of PBS. An 
1/2 inch 27-gauge needle was inserted into the dorsal 
aspect of the foot for injection. Three weeks later, 
after allowing the cells to grow into the primary site, 
mice were lightly anesthetized with the inhalation 
anesthetic, Metofane (Methoxyfurane) (Pitman-Moore, Inc., 
Washington Crossing, NJ) and the tumor-bearing foot was 
amputated with a pair of scissors. The wound was 
cauterized and drawn together with wound clips (Becton 
Dickinson & Co., Parsippany, NJ). Mice were injected with 
15 ug of Buprenex (Buprenorphine HCl, Reckitt & Colman 
Pharmaceutical, Inc., Norwich, NY) to relieve the pain and 
returned to their cages. After an additional 3-4 weeks, 
the animals were sacrificed by an overdose of ether. The 
lungs were removed and fixed in Bouin's solution 
overnight. The number of surface tumor colonies were 
counted under a dissecting microscope. 
Culture Qf. Lung Colony Tum.or Cells 
C57BL/6 mice were injected with 100,000 cells of 
Clone 7 of pSV2-uPA transfected B16-Fl cells or pSV2-neo 
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transfected Bl6-Fl cells. Animals were sacrificed 17 days 
after injection. The lungs were removed aseptically, cut 
into small pieces with sterile razor blades, and plated in 
vitro on petri dishes containing MEM supplemented with 10% 
heat-inactivated FBS. The medium was changed after the 
cultures adhered to the petri dishes. The cells were 
maintained in the same manner as Bl6-Fl cells when the 
cultures became confluent. 
cytotoxicity Assay 
The cytotoxicity assay was performed to test the 
immunologic responses in C57BL/6 mice against transf ected 
murine cells which produce human urokinase. The procedure 
is similar to that described by Hirschberg et al. (1977). 
Spleens were collected at the time of sacrifice from the 
mice which were injected with transfected cells. 
Lymphocytes were harvested from the spleens and served as 
cytotoxic effectors. The targets cells, Bl6-Fl 
transfected with pSV2-neo or clone 7 of pSV2-uPA 
transfected cells, were labeled with 51cr. Cytotoxic 
effectors were mixed with target cells at the ratio of 
50:1, 25:1, 12:1 or 6:1 and incubated for 4 hours at 37°C. 
The mixture was centrifuged and the supernatant was 
harvested and counted for radioactivity in a gamma counter 
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and % specific release was calculated. The spleen from 
the uninjected animal and B16-Fl untransf ected cells were 
used as a control . 
.s_tatistical Analysis of Data 
Numerical data was expressed as the mean ± standard 
deviation or the mean ± standard error of several 
determinations. To compare the data between the control 
and experimental groups, student t test and Mann Whitney 
U-Test (nonparametric rank sum test) were used. P values 
of < 0.05 were considered to represent significant 
difference between two groups. 
Chapter IV 
RESULTS 
J. The Production of Human Urokinase in Murine B16-Fl 
Melanoma Cells and The Study of Its Effect on Tumor 
cell Metastasis 
Expression of Human Preprourokinase Gene 
To express the human preprourokinase gene in B16-Fl 
melanoma cells, the plasmid pSV2-uPA which contains human 
preprourokinase cDNA in a sense direction with respect to 
the SV40 early gene promoter, was prepared. For the 
synthesis of pSV2-uPA, the dihydrofolate reductase gene of 
the plasmid pSV2-dhfr was replaced by the preprourokinase 
gene isolated from the plasmid pRdzbuktt. The detailed 
steps involved in subcloning preprourokinase cDNA into 
pSV2 vector are summarized in Figure 2. The correct 
plasmid which contained the preprourokinase gene in the 
sense direction was selected by restriction endonuclease 
digestion profile which is shown in Figure 3. 
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To introduce the human preprourokinase gene into 
Bl6-Fl melanoma cells, transfection technique was used. 
Transf ection was carried out by using calcium phosphate 
precipitation with DNA followed by a glycerol shock. 
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cells were cotransfected with plasmids pSV2-uPA and a 
selection marker gene pSV2-neo in 10:1 ratio, or 
transfected with the pSV2-neo alone for the control. In 
the pSV2-neo, SV40 early gene promotes the expression of 
an aminoglycoside phosphotransferase from the E...... coli 
transposable element Tn5. Expression of aminoglycoside 
phosphotransferase confers upon mammalian cells resistance 
to the toxic aminoglycoside G-418 (Geneticin), a neomycin 
analog. Therefore the pSV2-neo recipient mammalian cells 
gain the capability to survive in Geneticin upon 
successful transfection. To select transfected colonies, 
cells were grown in the presence of Geneticin (G-418) for 
four to five weeks. The transfection efficiency in the 
Bl6-Fl cell line by the transfection condition described 
on Materials and Methods section is shown to be about one 
transformant in 5,000 transfected cells when the closed 
circular plasmid DNA was used for transfection. The 
linerized plasmid DNA gave significantly low transfection 
efficiency (data not shown). The efficiency of 
transf ection was not increased by using a carrier DNA such 
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as 10 ug/ml of salmon sperm DNA for transfection (data not 
shown). A change of fresh MEM prior to transfection did 
not affect transfection efficiency (data not shown). 
cells appeared to be damaged and were lifted off from the 
petri dish if they were shocked longer than 5 minutes. 
The best transfection results were obtained when the cells 
underwent at least two cell divisions if thawed from the 
frozen stock and appeared very healthy before the 
transfection. 
The surviving colonies expressing the neo gene were 
assayed for the coexpression of the human preprourokinase 
gene by a filter immunoblot assay as shown in Figure 9. 
In this assay, all the proteins being secreted from the 
colonies expressing preprourokinase gene were absorbed to 
nitrocellulose filter. The filter was treated with 
polyclonal antibody to human urokinase to select for the 
positive colonies that produce human urokinase. Figure 9 
shows that pSV2-uPA and pSV2-neo transf ected cells 
generated many positive colonies detected by the dark 
color development. However pSV2-neo transfected control 
cells show the absence of color development which 
indicates these cells do not produce human urokinase. 
Twenty positive colonies detected for human 
urokinase secretion by filter immunoblot assay were 
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Figure 9. Filter i:mmunoblot analysis of transfected 
B16-F1 cell colonies 
Bl6-Fl cells were transfected with pSV2-neo 
(top) or cotransfected with pSV2-uPA and pSV2-neo 
(bottom). Transfected cells were cultured in MEM 
supplemented with 10% heat inactivated FBS 
containing Geneticin (G-418). Five weeks later, 
nitrocellulose membrane filters were placed over the 
cell colonies to absorb urokinase being secreted. 
The filters were treated with rabbit polyclonal 
antibody to human urokinase followed by goat anti-
rabbi t IgG conjugated with alkaline phosphatase, 
which were reacted with NBT/BCIP to give dark purple 
color development. The spots on the filters 
correspond to the transf ected foci expressing human 
urokinase. 
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selected, transferred to separate petri dishes, and 
expanded in MEM supplemented with 10% heat inactivated 
FBS. Secretion of human urokinase into the cell culture 
medium from each colony was then quantitated by a sandwich 
type ELISA using a monoclonal antibody against high 
molecular weight human urokinase as the primary antibody 
and polyclonal antibody against high and low molecular 
weight human urokinase as the detecting antibody. 
Monoclonal antibody to human urokinase has been reported 
to identify the single-chain prourokinase as well as two-
chain urokinase (Sallerno et al., 1984). The ELISA Kit 
(American Diagnostica Inc.) was used for the assay to 
detect both single and two-chain urokinase. Table 1 shows 
that clone 7, 8, 10, and 18 secreted the highest amount of 
human urokinase out of 20 positive selected clones. Bl6-
Fl or Bl6-Fl0 untransfected cells give absorption value 
equal to zero, as no human urokinase is produced. 
The incorporation of human preprourokinase gene to 
genomic DNA of transfected cells was demonstrated by a 
Southern blot hybridization assay as shown in Figure 10. 
The DNAs were prepared from clone 7 of pSV2-uPA 
transfected cells and Bl6-Fl untransfected cells, digested 
with BamHI or PstI, separated by electrophoresis, blotted, 
and probed with 32P labeled human preprourokinase cDNA. 
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Table 1. Quantification of human urokinase production by 
B16-F1 transfected cells with pSV2-uPA detected by ELISAa 
Clone Absorbance Clone Absorbance 
No (Mean±SD) No (Mean±SD) 
Cl 1.79 ± 0.06 Cll 2.71 ± 0.15 
C2 0.25 ± 0.03 Cl2 0.14 ± 0.15 
C3 1.17 ± 0.01 Cl3 2.81 ± 0.06 
C4 0.72 ± 0.04 Cl4 0.13 ± 0.02 
C5 0.87 ± 0.04 Cl5 0.34 ± 0.05 
C6 0.09 ± 0.03 Cl6 0.72 ± 0.07 
C7 4.24 ± 0.28 Cl7 0.51 ± 0.02 
C8 2.97 ± 0.12 Cl8 3.22 ± 0.24 
C9 0.10 ± 0.03 Cl9 1.57 ± 0.08 
ClO 3.43 ± 0.13 C20 1.63 ± 0.05 
Bl6Fl 0.08 + o.03b Bl6Fl0 0.08 ± o.o4b 
aThe secretion of urokinase from each colony was 
quantitated by IMUCLONE uPA ELISA Kit (American 
Diagnostica Inc.) on conditioned media taken from the 
cells incubated in the serum free media for 40 hours. 
bvalue equal to zero as no human urokinase is produced by 
murine Bl6-Fl cells which were not transfected with the 
pSV2-uPA plasmid. 
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Figure 10. southern blot hybridization analysis of 
DNA isolated from clone 7 of pSV2-uPA transf ected 
B16-F1 and B16-F1 untransf ected cells 
DNAs were isolated from clone 7 of 
transf ected Bl6-Fl cells and untransf ected Bl6-Fl 
cells. The DNAs (10 ug) were cleaved with PstI or 
BamHI and electrophoresed through 0.8% agarose gel. 
A control pSV2-uPA plasmid preparation was similarly 
digested with PstI or BamHI and different amounts 
were loaded on the same gel. The DNAs were 
transferred to nitrocellulose and probed with 32P-
labeled HpaI-PstI fragment of pSV2-uPA. Lanes 1-2 
contain DNA made from 7 x 106 cells of clone 7 of 
pSV2-uPA transf ected cells and lanes 3-4 contain DNA 
made from 7 x 106 untransfected cells. Lanes 5-6 
contain DNA made from 3.5 x 106 cells of clone 7 and 
lanes 7-8 from 3.5 x 106 untransfected cells. Lanes 
9-10, lanes 11-12, lanes 13-14 contain pSV2-uPA DNA 
of 10, 5, 2 ng respectively. Lanes 1,3,5,7,9,11,13 
contain DNA digested with BamHI and lanes 
2,4,6,8,10,12,14 contain DNA digested with PstI. 
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The digestion of pSV2-uPA with BamHI generates two DNA 
bands with base pairs of 4647 and 896 and the 32P-labeled 
probe hybridizes with both bands. The digestion of pSV2-
uPA with PstI generates three DNA bands with base pairs of 
2327, 2258, and 958 and the 32P-labeled probe hybridizes 
with 2327 and 2258 bands. As shown in Figure 10, clone 7 
DNA digested with BamHI (lanes 1 and 5) showed two DNA 
bands of 4647 and 896 base pairs same as BamHI digested 
pSV2-uPA (lanes 9, 11, and 13). Again clone 7 DNA 
digested with PstI (lanes 2 and 6) showed one combined 
band of 2327 and 2258 base pairs same as PstI digested 
pSV2-uPA (lanes 10, 12, and 14). Therefore clone 7 
demonstrates the restriction endonuclease digested bands 
identical to those of pSV2-uPA while the untransf ected 
cells (lanes 3, 4, 7, and 8) show the absence of these 
bands. 
The DNA copy numbers of human preprourokinase cDNA 
in clone 7 were estimated from a densitometer scan of 
autoradiographs by comparing the amounts of hybridization 
of a 32P-labeled probe to the genomic DNA of clone 7 cells 
(lanes 2 and 6) with known amounts of pSV2-uPA plasmids 
(lanes 10, 12, and 14). Figure 11 demonstrates the 
densitometer scan of lanes 2 (peak A), 6 (peak B+C), 10 
(peak D), 12 (peak E), and 14 (peak F) of Figure 10 
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Figure 11. Densitometer scan of autoradioqraphs of 
32P hybridized to .the genomic DNA of clone 7 or 
pSV2-uPA plasmid DNA 
The DNA copy numbers of human preprourokinase 
cDNA in clone 7 were estimated from a densitometer 
scan of autoradiographs by comparing the amounts of 
hybridization of a 32-labeled probe to the genomic 
DNA of clone 7 cells with known amounts of pSV2-uPA 
plasmids. Peak A (lane 2 of Figure 10) with peak 
area of 12.9 represents DNA prepared from 7 x 106 
cells, peak B+C (lane 6 of Figure 10) with peak area 
of 7.12 represents DNA made from 3.5 X 106 cells. 
Peaks D (lane 10 of Figure 10), E (lane 12 of Figure 
10), and F (lane 14 of figure 10) which show peak 
area of 15.0, 8.93, and 2.40 represent 10, 5, and 2 
ng of pSV2-uPA DNA respectively. 
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showing peak areas of 12.9, 7.12, 15.0, 8.93, and 2.40 
respectively. Peak A and peak B+C represent DNAs prepared 
from 7 x 10 6 cells and 3.5 x 106 cells of clone 7. Peaks 
o,E, and F represent 10 ng, 5 ng, and 2 ng of pSV2-uPA 
respectively, and accordingly approximately 1 x 109 , 5 x 
108, 2 x 108 copies of pSV2-uPA. By the comparison of 
peak areas of A and B+C with D, E, and F, the copy numbers 
of pSV2-uPA in clone 7 lanes were estimated. The 
estimated copy numbers were divided by the clone 7 cell 
numbers from which the DNA was prepared to calculate the 
copy numbers present per cell of clone 7. The 
calculations by the comparison of A with D, E, or F gave 
copy numbers of 131, 123, or 168 respectively and by the 
comparison of B+C with D, E, or F gave copy numbers of 
149, 156, or 185. On average, therefore, approximately 
150 copies of pSV2-uPA were shown to be incorporated 
within the genomic DNA of clone 7. 
The expression of human preprourokinase mRNA was 
determined by Northern blot hybridization assay as shown 
in Figure 12. The cytoplasmic RNAs from clones 7 and 10 
of pSV2-uPA transfected cells, pSV2-neo transfected cells, 
and untransfected Bl6-Fl cells were extracted, separated 
by formaldehyde/agarose gel, transferred to filter, and 
probed with 32P-labeled human preprourokinase cDNA. The 
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Figure 12. Northern blot hybridization analysis of 
RNA isolated from clone 7 and clone 10 of pSV2-uPA 
transfected cells, pSV2-neo transfected cell, and 
B16-F1 untransf ected cells 
The cytoplasmic RNAs of B16-Fl, B16-Fl 
transfected cells were extracted, separated by The 
filter was hybridized with 32P-labeled human 
preprourokinase cDNA probe and exposed to X-ray 
film. The 2.3 Kb band on the clone 7 and clone 10 
lanes demonstrates human urokinase mRNA expression, 
while this band is absent in B16-Fl or B16-Fl pSV2-
neo transfected cell RNA. For the internal 
standard, 32P-labeled Drosophila actin was used. 
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ianes with clone 7 and 10 RNAs show distinct bands which 
represent a 2.3 Kb mRNA of human preprourokinase gene 
while the lanes with Bl6-Fl untransfected cells and pSV2-
neo transfected cells show absent of that band. The 
internal standard of 32P-labeled Drosophila actin shows 
that similar amounts of RNA were applied to each lane of 
the gel. 
Figure 13 shows a densitometer scan of 
autoradiographs of a 32P-labeled probe to the RNA of clone 
7, 10 or pSV2-neo transfected cells. The densitometer 
scan of human urokinase RNA of clone 7 (lane 3 of Figure 
12, peak A) and clone 10 (lane 4 of Figure 12, peak B) 
gave the peak area of 1.71 and 1.88 respectively. The 
densitometer scan of Drosophila actin RNA of lane 3 of 
Figure 12 (peak D+E) and lane 4 of Figure 12 (peak F+G) 
gave the peak area of 0.97 and 1.27 respectively. The 
relative amount of human preprourokinase mRNA expression 
in clone 7 and 10 was estimated by calculating the ratio 
of peak areas of human urokinase to actin. The ratio of 
peak A/peak D+E (1.71/0.97) and peak b/peaks F+G 
(1.88/1.27) gave the value of 1.76 and 1.48 which indicate 
human preprourokinase mRNA expression of clone 7 and clone 
10 respectively. The ELISA data (Table 1) showed C7 and 
Clo secreted human urokinase activity with absorbance 
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Figure 13. Densitometer scan of autoradiographs of 
.
32p hybridized to the RNA of clone 7, 10, or pSV2-
neo transfected cells 
The relative amount of RNA of human 
preprourokinase in clone 7 and clone 10 were 
estimated from a densitometer scan of 
autoradiographs by comparing the amounts of 
hybridization of a 32P-labeled probe to the internal 
standard of Drosophila actin RNA. In the top 
figure, peak A (lane 3 of Figure 12) with peak area 
of 1.71 represents human urokinase RNA prepared from 
clone 7 cells, peak B (lane 4 of Figure 12) with 
peak area of 1.88 represents human urokinase RNA 
made from clone 10 cells. In the bottom figure, 
peaks D+E (lane 3 of Figure 12), F+G (lane 4 of 
Figure 12) which show peak area of 0.97 and 1.27 
represent Drosophila actin. 
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value of 4.24 and 3.43 respectively. The ratio of human 
urokinase versus mRNA was calculated to be 2.41 
(4.24/1.76) for C7 and 2.32 (3.43/1.48) for ClO. The 
ratio of mRNA expression and human urokinase secretion 
between C7 and ClO is shown to be similar: 1.19 
(1.76/1.48) for mRNA and 1.24 (4.24/3.43) for urokinase. 
characterization of Human Urokinase produced ~ Murine 
Cells 
90 
Human urokinase is a glycoprotein (Holmes et al., 
1985) whereas the murine urokinase lacks glycosylation 
sequences and is not glycosylated (Belin et al., 1985). 
Since the human urokinase is synthesized by transfected 
murine cells, the possible glycosylation of the human 
urokinase was tested by Concanavalin A column 
chromatography, which tightly binds polysaccharides and 
glycoproteins containing alpha-D-mannopyranosyl, alpha-D-
glucopyranosyl and sterically related residues (Narasimha 
et al, 1979). Tightly bound glycoproteins can be eluted 
by the addition of alpha-methyl-D-mannoside to the buffer 
(Aspberg and Porath, 1970). The added alpha-methyl-D-
mannoside will compete for the carbohydrate binding sites 
on the ConA, and cause the dissociation of any bound 
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glycoproteins. The column eluents before and after the 
addition of alpha-methyl-D-mannoside to the elution buffer 
were collected and assayed for the human urokinase by 
ELISA with specific monoclonal antibody to human 
urokinase. The results in Figure 14 show that human 
urinary urokinase (purchased from American Diagnostica, 
Inc.) contained a non-binding form of urokinase that was 
eluted prior to the alpha-methyl-D-mannoside wash, and a 
second peak eluted with alpha-methyl-D-mannoside buffer 
which corresponds to a glycosylated urokinase. The first 
unglycosylated urokinase peak might be generated from the 
urokinase from which carbohydrate moiety was degraded 
during the protein purification procedures or storage. 
The pSV2-uPA transf ected murine B16-Fl clones produced 
only one human urokinase peak which was eluted with alpha-
methyl-D-mannoside and coincided with the glycosylated 
urokinase peak observed in the human urokinase 
preparation. This result demonstrates that human 
urokinase produced by the transf ected murine Bl6-Fl cells 
is glycosylated. 
Specific urokinase receptors have been described in 
several cell lines (Vassalli gt al., 1985; Stoppelli et 
al., 1985) and receptor binding has been shown to be 
species specific (Huarte et al., 1987; Estreicher et al., 
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Figure 14. concanavalin A affinity chromatography 
of human urokinase from commercially purified 
preparation (A) and from pSV2-uPA transfected Bl6-Fl 
conditioned medium (B) 
commercial human urokinase (A) or the serum-
free conditioned medium collected from clone 7 of 
pSV2-uPA transfected Bl6-Fl cells (B) was applied to 
the Con A column. The columns were washed with Tris 
buffer and then same buffer containing alpha-methyl-
D-mannoside (arrow). Each fraction was collected 
and assayed for human urokinase by the ELISA using 
monoclonal antibody to human urokinase. 
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1989). Since human urokinase is produced by the 
transfected murine cells, the ability of human urokinase 
to bind to murine cell surf ace receptors was studied by a 
competitive binding assay. Cells were treated with mild 
acid to unmask cell surface receptor sites and assayed for 
the receptor binding with 125I labeled human urokinase in 
the presence of different concentrations of unlabeled 
human urokinase. The results (Figure 15) showed that the 
human urokinase binds to a human cell line PC-3-Met 
(Kozlowski et al., 1984), derived from a human prostate 
carcinoma. In contrast, the human urokinase showed no 
specific affinity to the cell surface of the murine Bl6-Fl 
cells. This result demonstrates that the human urokinase 
does not bind to the cell surface of murine Bl6-Fl cells. 
Determination of Urokinase Activity 
It was of interest to measure the increase in 
plasminogen activator activity, due to the transfection of 
pSV2-uPA, over the endogenous murine plasminogen activator 
activity which is normally produced by Bl6-Fl cells. The 
activity was determined with a chromogenic substrate for 
plasmin which is generated from plasminogen by the 
urokinase secreted from the transfected cells. Figure 16 
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Figure 15. Specific binding of human urokinase to 
human PCJ-Met and murine B16-Fl cells 
Binding of human urokinase (uPA) to the human 
PC3-Met cell surface (0) and the murine B16-Fl cell 
surface (0) was determined by receptor binding 
assay. Cells were treated with mild acid to unmask 
the receptors on the cell surface. PC3-Met and Bl6-
Fl cells were incubated with 1251-labeled human 
urokinase and different concentration of unlabeled 
human urokinase. Cells were washed with PBS/BSA and 
lysed with detergent. Lysed cells were counted in a 
gamma-counter. Nonspecific binding was determined 
in the presence of excess (50 nM) unlabeled human 
urokinase and subtracted from the each experimental 
value. Data are expressed as the mean of triplicate 
determinations and standard deviations of the mean. 
The human urokinase appears to specifically bind 
only to the human PC3-Met cells, but not murine B16-
Fl cells. 
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·Figure 16. Secreted plasminogen activator activity 
of Bl6-Fl and pSV2-uPA transfected Bl6-Fl cells as 
determined against a chromogenic substrate 
B16-Fl, B16-F10 or transfected B16-Fl cell 
conditioned media were incubated with the plasmin 
specific chromogenic substrate S-2251 (H-D-Val-Leu-
Lys-p-nitroanilide) and DFP treated plasminogen. 
After the incubation, the p-nitroaniline absorbance, 
corresponding to substrate hydrolysis by plasmin 
which was activated from plasminogen by urokinase 
produced from conditioned media, was measured. 
Nonspecific activity was measured in the absence of 
cell conditioned media and subtracted from the 
experimental value. Plasminogen activator activity 
was expressed in pg secreted to conditioned medium 
per cell per hour. 
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and Table 2 shows an increase in secreted plasminogen 
activator activity of 3 to 4-fold in clones 7 and 10 over 
cells transfected with pSV2-neo alone or untransfected 
Bl6-Fl cells. Three to four fold increase in clone 7 and 
10 raises the plasminogen activator activity to the level 
present in the more highly metastatic Bl6-Fl0 cell line. 
The result also shows that transfection of pSV2-neo did 
not affect urokinase production in Bl6-Fl cells. Most of 
cells used for the assay were passaged five to seven 
times. 
The results of the synthetic substrate assay were 
confirmed by 125I-fibrin assay for plasmin (Figure 17 and 
Table 3). In this assay, the plasminogen activator 
activity was determined by measuring degradation of fibrin 
those shown in Figure 16 and Table 2 were obtained by 
125I-fibrin plate assay. 
From the ELISA data of Table 1, two clones (clones 
9 and 12) that produce the least amount of human urokinase 
and two clones (clones 8 and 18) that produce the highest 
amount of human urokinase (excluding clone 7 and 10) were 
selected for further study. The plasminogen activator 
activity was determined with a chromogenic substrate for 
plasmin for the clones 8, 9, 12, and 18 and compared to 
that of clone 7 or pSV2-neo transfected Bl6-Fl cells. The 
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Table 2. Quantification of secreted plasminogen activator 
(PA) activity of Bl6-Fl, B16-F10, and transfected B16-Fl 
cells by chromogenic substrate assaya 
Cell 
B16-Fl 
B16-Fl (pSV2-neo) 
Bl6-F10 
Clone 7 (pSV2-uPA) 
Clone 10 (pSV2-uPA) 
Secreted PA activityb 
(Mean ± SD) 
3.90 + 0.36c,d 
4.42 ± 0.54c,e,f 
11.9 ± 1.06d 
13.1 ± 0.98e,g 
12.1 + 2.29f ,g 
acell conditioned media collected from B16-Fl, B16-FlO, 
and B16-Fl transfected cells with pSV2-neo or pSV2-uPA 
(clone 7 and clone 10) were incubated for 16 hours with 
the plasmin specific chromogenic substrate S-2251 (H-D-
Val-Leu-Lys-p-ni troanilide) and DFP treated plasminogen. 
After the incubation, the p-nitroaniline absorbance, 
corresponding to substrate hydrolysis by plasmin, was 
measured. 
bPlasminogen activator activity is expressed in lxlo-2 pg 
secreted to conditioned medium per cell per hour. 
cNot significantly different (p = 0.11) 
dsignificantly different (p = o.ooo) 
esignificantly different (p = 0.000) 
fsignificantly different (p = o.ooo) 
gNot significantly different (p = 0.25) 
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Figure 17. Secreted plasminogen activator activity 
of Bl6-Fl and pSV2-uPA transfected B16-Fl cells as 
determined by 1251-fibrin plate assay 
Conditioned media from Bl6-Fl, Bl6-Fl pSV2-neo 
transfected, Bl6-Fl0, clone 7 and clone 10 of B16-Fi 
pSV2-uPA transfected cells were incubated with DFP-
treated plasminogen in 1251-fibrin plate. The 
ability of plasmin, which was activated from 
plasminogen by the urokinase produced from 
conditioned media, was measured by the released 
soluble 1251-fibrin degradation product. 
Nonspecific activity was measured in the absence of 
cell conditioned media and subtracted from the 
experimental value. Plasminogen activator activity 
was expressed in pg secreted to conditioned medium 
per cell per hour. 
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Table 3. Quantification of secreted plasminogen activator 
(PA) activity of B16-Fl, B16-F10, and transfected B16-Fl 
cells as determined by 1251-fibrin plate assaya 
Cell 
B16-Fl 
B16-Fl (pSV2-neo) 
B16-F10 
Clone 7 (pSV2-uPA) 
Clone 10 (pSV2-uPA) 
Secreted PA activityb 
(Mean ± SD) 
4.02 ± 0.24c,d 
4.81 ± 0.18c,e,f, 
11.6 ± 0.67d 
11.7 ± 0.45e,g 
10.8 ± 0.39f ,g 
acell conditioned media collected from B16-Fl, B16-F10, 
and B16-Fl transfected cells with pSV2-neo or pSV2-uPA 
(clone 7 and clone 10) were incubated with DFP-treated 
plasminogen in 1251-fibrin plate. The ability of plasmin, 
which was activated from plasminogen by the plasminogen 
activator produced from conditioned media, was measured by 
the released soluble 125r-fibrin degradation product. 
bPlasminogen activator activity is expressed in 1x10-2 pg 
secreted to conditioned medium per cell per hour. 
cNot significantly different (p = 0.30) 
dsignif icantly different (p = 0.000) 
esignif icantly different (p = 0.000) 
f significantly different (p = 0.000) 
gNot significantly different (p = 0.52) 
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results in Table 4 show clones 8 and 18 secreted the same 
amount of plasminogen activator activity as clone 7. 
clones 9 and 12 also secreted the same amount of 
plasminogen activator activity as pSV2-neo transfected 
cells. The difference in enzyme activity between clones 8 
and 18 and clones 9 and 12 indicates that the increased 
secretion of plasminogen activator activity of clones 7 
and 10 is due to the human urokinase expression of the 
transfected clones. 
To test the stability of the urokinase gene 
expression, the chromogenic assay was performed with the 
to soluble peptides by plasmin which was activated from 
plasminogen by the secreted urokinase. Results similar to 
conditioned medium collected from the C7 passaged more 
than 20 times in cell culture. The urokinase activity 
from that particular sample was similar to those of early 
passaged cells (data not shown). 
In vivo Metastasis Assay 
This assay assesses the effect of the secreted 
human urokinase from Bl6-Fl pSV2-uPA transfected cells on 
lung colonization, which measures tumor cell extravasation 
from the blood and then growth into pulmonary tumors. 
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Table 4. Quantification of secreted plasminogen activator 
(PA) activity of pSV2-uPA transfected B16-Fl cells (clones 
1, 8, 9, 12 and 18) by chromogenic substrate assaya 
Cell Secreted PA activityb 
(Mean ± SD) 
Clone 7 6.42 ± 1 . 61c,d,e,f 
Clone 8 6.06 ± 0.60c,d,e 
Clone 9 2.90 + 0.22g 
Clone 12 2.89 ± 0.24h 
Clone 18 6.02 ± 0.75c,d,f 
B16-Fl 2.49 ± 0.59c 
B16-Fl (pSV2-neo) 2.84 ± 0.46g,h 
acell conditioned media collected from 1 x 10 6 B16-Fl 
transfected cells with pSV2-neo or pSV2-uPA (clone 7, 8, 
9, 12 and 18) for 24 hours in 10 mm petri dishes were 
incubated for 16 hours with the plasmin specific 
chromogenic substrate S-2251 and DFP treated plasminogen. 
After the incubation, the p-nitroaniline absorbance, 
corresponding to substrate hydrolysis by plasmin, was 
measured. 
bPlasminogen activator activity is expressed in lxlo-2 pg 
secreted to conditioned medium per cell per hour. 
cclones 7, 8, and 18 are different from B16-Fl at p = 
0.000. 
dclones 7, 8, and 18 are different from B16-Fl (pSV2-neo) 
at p = 0.000. 
eNot significantly different (p = 0.35) 
fNot significantly different (p = 0.41) 
gsignif icantly different (p = 0.009) 
hsignif icantly different (p = 0.015) 
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C57BL/6 mice were tail vein injected with 100,000 tumor 
cells from clones 7, clone 10, or control cells. The 
control cells transfected with pSV2-neo only, were made up 
of a mixture of cells from randomly selected pSV2-neo 
transfected clones, so as not to bias the controls in any 
one direction. Cells injected into the animal had been 
passaged 4 to 5 times in cell culture following the 
transfection. Thirteen mice each, were used for each 
control or experimental group, in every experiment. 
Attention was given to the cell culture conditions, such 
as confluency of the cells, and number of passages which 
were kept identical for both control and experimental 
cells in each experiment. To assess the metastatic 
potential of transfected cells, the number of lung tumors 
which appeared on the lung surface were counted under the 
dissecting microscope. An earlier study compared the 
results of microscopic examination of lung section to the 
observation of lung surface tumors and found a close 
correlation between the two results (Wexler, 1966). 
Table 5 compares the number of metastatic tumors 
formed in the lungs of C57BL/6 mice. The pSV2-neo 
transf ected cell mixture had a similar lung colonization 
ability to that previously reported for untransfected Bl6-
Fl cells (Fidler, 1983). Thus transfection alone does not 
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Table 5. Lung Colonization by B16-F1 Murine Melanoma 
cells Transfected with Human Preprourokinase cDNA in a 
SV40 Expression Vectora 
Vector Number of Tumors Mean + S.E. 
Experiment .l 
pSV2-neo 1,1,2,3,3,3,4,4,4,4,9, 4.92 ± 1.16b 
(control) 11,15 
pSV2-neo & 26,55,58,59,60,84,87,92, 87.9 + 10.7b 
pSV2-uPA 99,102,112,137,172 
(Clone 7) 
Experiment 2. 
pSV2-neo 2,3,7,7,10,10,14,14,16, 10.5 + i. 88b 
(control) 21 
pSV2-neo & 8,25,27,28,28,30,31,39, 39.5 ± 6.59b 
pSV2-uPA 45,58,59,96 
(Clone 10) 
aAnimals were injected i.v. in the tail vein with 100,000 
B16-Fl transfected cells. Mice were killed 17 days after 
the injection and the number of lung metastatic foci was 
counted. 
bDifferent at p < 0.001 by both the Mann Whitney U-Test 
(nonparametric rank sum test) and Student t-test. 
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appear to significantly increase the metastatic potential 
of the B16-Fl cells. However, both clones 7 and 10, which 
were selected for their high secretion of human urokinase, 
showed a dramatic and significant (p < 0.001) increase in 
lung colonization ability compared to controls. 
To confirm our finding that the increased 
plasminogen activator activity due to the production of 
urokinase enhanced metastatic potential for clones 7 and 
10, clones 8 and 12 were also tested for lung 
colonization. Clones 8 and 12 were selected for their 
high and low secretion of human urokinase respectively 
even though they were transfected with the same vectors, 
pSV2-uPA and pSV2-neo. The results in Table 6 compare the 
number of metastatic tumors formed by clones 8 and 12. 
Clone 8 showed a significant (p = 0.0019) increase in lung 
colonization ability compared to clone 12. 
Figure 18 shows typical lungs dissected from 
control mice which were injected with pSV2-neo transfected 
B16-Fl cells and experimental mice which received tumor 
cells from clone 7. Tumors from experimental mice are 
shown to be mixture of amelanotic and melanotic while 
tumors from control mice are mainly melanotic. All tumors 
from the control mice and experimental mice were divided 
into melanotic or amelanotic groups and the number of 
Table 6. Lung Colonization by B16-F1 cells transfected 
with pSV2-uPA and pSV2-neo (clone 8 and 12)a 
Vector Number of Tumors Mean ± S.E. 
pSV2-neo & 12,34,46,74,94,98,101, 88.6 ± 14.9b 
pSV2-uPA 132,144,151 
(clone 12) 
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pSV2-neo & 119,128,142,181,185, 206.9 ± 28.5b 
pSV2-uPA >300,>300,>300 
(Clone 8) 
aAnimals were injected i.v. in the tail vein with 100,000 
B16-Fl transfected cells. Mice were killed 17 days after 
the injection and the number of lung metastatic foci was 
counted. 
bDifferent at p = 0.0019 by student t-test and p < 0.01 by 
the Mann Whitney U-Test (nonparametric rank sum test). 
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Figure 18. Gross appearance of typical lungs 
dissected from control (left) and experimental 
(right) mice 
Control mice were injected with 105 B16-Fl 
cells transfected with pSV2-neo and experimental 
mice received io5 clone 7 cells transfected with the 
pSV2-neo and pSV2-uPA plasmids. 
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tumors in each group were counted. Table 7 shows the 
percent of tumors in the two different color groups. It 
was observed that high urokinase secreting clones (clones 
7, 10, and 8) produced predominantly amelanotic tumors 
while pSV2-neo transf ected clones or low urokinase 
secreting clone (clone 18) produced mainly melanotic 
tumors. 
Cytotoxicity assay was performed to test if murine 
cells that produce human urokinase might generate any 
immunologic response in C57BL/6 mice. The 51cr release 
result shows no indication of immunological response 
against the human urokinase produced by transf ected murine 
cells (data not shown). (Assay was carried out by the 
clinical laboratory staff in Dr. John Clancy's lab., 
Department of Anatomy). 
Spontaneous metastasis from foot pad tumor formed 
by clone 7 cells was assayed to study the effect of 
secreted urokinase on the full metastatic process. Table 
8 shows the number of pulmonary tumors formed in the 
spontaneous metastasis experiment from primary tumors 
grown in the hind leg foot pad of C57BL mice. Clone 7 
cells demonstrated an absolute ability to metastasize (all 
experimental mice showed spontaneous metastasis), while 
foot pad tumors produced by control Bl6-Fl pSV2-neo 
Table 7. Color distribution of metastatic tumors in 
murine lung from mice tail-vein injected with B16-Fl 
transfected cellsa 
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Cells 
Injected 
Percentage of tumors in color category 
Melanotic Amelanotic 
(Mean ± s . D. ) 
pSV2-neo 97.1 ± 6.98 2.91 ± 6.98 
(control) 
pSV2-neo & 29.4 ± 6.85 70.6 ± 6.81 
pSV2-uPA (C7) 
pSV2-neo 93.1 ± 8.57 6.46 ± 8.80 
(control) 
pSV2-neo & 37.7 + 8.79 62.5 ± 9.17 
pSV2-uPA (ClO) 
pSV2-neo & 91.0 ± 4.84 9.83 + 4.86 
pSV2-uPA (Cl2) 
pSV2-neo & 7.66 ± 4.26 92.2 + 4.49 
pSV2-uPA (CS) 
aColor of the lung tumors from control and experimental 
groups were divided into two groups, melanotic and 
amelanotic and tumor numbers were counted. Results are 
expressed in percent ± S.E. of tumor numbers in the 
different color groups. 
Table 8. Spontaneous pulmonary metastasis by B16-Fl 
Murine Melanoma Cells Transfected with Human 
Preprourokinase cDNA in a SV40 Expression Vectora 
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vector number of colonies mean ± S.E. 
pSV2-neo o,o,o,o,o,o,o,o,o,2,11 1.18 ± l.OOb 
(control) 
pSV2-neo + l,l,2,2,3,3,3,7,11,23, 9.58 ± 3.26b 
pSV2-uPA 26,33 
(Clone 7) 
aMice were injected subcutaneously into a footpad with 
100,000 cells of transfected cells. Three weeks later, 
tumor-bearing foot was amputated. Seven weeks after the 
injection, animals were killed and the number of lung 
metastatic foci were counted. 
bDifferent at p < 0.001 by the Mann Whitney U-Test 
(nonparametric rank sum test) and at p < 0.03 by the 
Student t-test. 
transfected cells showed a low ability to spontaneously 
metastasize (only 2 mice out of 11 showed pulmonary 
tumors). 
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Demonstration of Human Urokinase Activity in Murine LYng 
TUJ!!,ors 
To determine the presence of human urokinase 
produced by the pSV2-uPA transf ected cells in murine lung 
metastatic tumors of clone 7, cells from the lung nodules 
were plated in vitro and assayed for the human urokinase 
by ELISA using monoclonal antibody. The ELISA results in 
Table 9 shows that clone 7 cells passaged through animal 
secreted similar amount of human urokinase as the original 
clone 7 cells. The plasminogen activator activity from 
both cells also was measured by chromogenic substrate 
assay. Table 10 shows that clone 7 cells, either primary 
or passaged through animal, secreted similar amounts of 
plasminogen activator activity. Taken together, these 
results indicate that the plasminogen activator activity 
detected in the lung nodules is contributed by the human 
urokinase from the pSV2-uPA transf ected cells and that the 
phenotype of transfected cells was stable in vivo. 
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Table 9. Quantification of human urokinase production by 
B16-Fl transf ected cells and the same cells passaged 
through animal (PTA) by ELISAa 
Cell 
Bl6-Fl (pSV2-neo) 
Bl6-Fl (pSV2-neo) PTAC 
Bl6-Fl (pSV2-uPA) C7 
Bl6-Fl (pSV2-uPA) C7 PTAc 
Absorbance 
(Mean±SD) 
0.01 ± o.01b,d,f 
0.01 ± o.01b,d,g 
0.58 ± o.ose,f 
0.63 ± 0.06e,g 
aThe secretion of urokinase from each colony was 
quantitated by IMUCLONE uPA ELISA Kit (American 
Diagnostica Inc.) on conditioned media taken from the 
cells incubated in the serum free media for 40 hours. 
bvalue equal to zero as no human urokinase is produced by 
murine Bl6-Fl cells which was transfected with the 
pSV2-neo plasmid. 
cThe lung tumors removed from the mice which were injected 
with the transfected cells were plated in vitro and 
cultured for the assay. 
dNot significantly different (p = 0.49) 
eNot significantly different (p = 0.30) 
f significantly different (p = 0.000) 
gsignif icantly different (p = 0.000) 
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Table 10. Quantification of secreted plasminogen 
activator (PA) activity of transfected cells and the cells 
passaged through animal (PTA) by chromogenic substrate 
assaya 
Cell 
Bl6-Fl (pSV2-neo) 
Bl6-Fl (pSV2-neo) PTAC 
Clone 7 (pSV2-uPA) 
Clone 7 (pSV2-uPA) PTAC 
Secreted PA activityb 
(Mean ± SD) 
2.49 ± o.6od,f 
2.84 ± 0.46d,g 
6.42 ± i. 61d,e,f 
6.71 ± l.73d,e,g 
acell conditioned media collected from 1 x 106 Bl6-Fl 
pSV2-neo, Bl6-Fl pSV2-neo and pSV2-uPA (clone 7) 
transfected cells, and the same cells passaged through 
animal (PTA) for 24 hours in 10 mm petri dishes were 
incubated for 16 hours with chromogenic substrate S-2251 
and DFP treated plasminogen. After the incubation, the p-
nitroaniline absorbance, corresponding to substrate 
hydrolysis by plasmin, was measured. 
bPlasminogen activator activity is expressed in lxlo-2 pg 
secreted to conditioned medium per cell per hour. 
cThe lung tumors removed from the mice which were injected 
with the above cells were plated in vitro and cultured for 
the assay. 
dNot significantly different (p = 0.29) 
eNot significantly different (p = 0.67) 
f Not significantly different (p = 0.90) 
gNot significantly different (p = 0.85) 
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II. Inhibition of Urokinase Production in Murine B16-F10 
Melanoma Cells and the Study of its Effect on Lung 
colonization 
Expression of Antisense Human Urokinase Gene 
The plasmid pSV2-ASuPA containing 5' end of 265-
base-pair of preprourokinase sequence in an antisense 
direction with respect to SV40 early gene promoter was 
prepared from the the plasmid pSV2-dhfr and pRdzbuktt as 
shown in Figure 7. In the synthesis of pSV2-ASuPA, the 
ligation on HindIII sites of pSV2-dhfr digest and 265 
base-pair of human urokinase cDNA automatically brings the 
pSV2-ASuPA in an antisense orientation. The final pSV2-
ASuPA plasmid construction which is shown in Figure 8 was 
confirmed by restriction endonuclease digestion map. 
Murine Bl6-Fl0 melanoma cells of high metastatic 
potential were similarly cotransfected with the plasmids 
pSV2-ASuPA and pSV2-neo in 10:1 ratio, glycerol shocked, 
and grown in the presence of Geneticin (G-418). The 
surviving colonies were assayed for the production of 
urokinase by a filter immunoblot assay using a polyclonal 
antibody to human urokinase as shown in Figure 19. It has 
been shown that polyclonal antibody to human urokinase 
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Figure 19. Filter i:mmunoblot analysis of 
transf ected B16-F10 cell colonies 
Bl6-Fl0 cells were transfected with pSV2-neo 
(top) or cotransfected with pSV2-ASuPA and pSV2-neo 
(bottom). Transfected cells were cultured in MEM 
supplemented with 10% heat inactivated FBS 
containing Geneticin (G-418). Five weeks later, 
nitrocellulose membrane filters were placed over the 
cell colonies to absorb urokinase being secreted. 
The filters were treated with rabbit polyclonal 
antibody to human urokinase followed by goat anti-
rabbi t IgG conjugated with alkaline phosphatase, 
which were reacted with NBT/BCIP to give dark purple 
color development corresponding to urokinase 
presence. Fifteen colonies that show light purple 
color which indicates lower production of urokinase 
were selected for further study. 
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cross reacts with mouse urokinase (Ossowski, 19SS). 
Fifteen colonies that demonstrated light purple color 
indicating decreased amounts of urokinase secretion were 
selected, transferred to separate petri dishes, and 
expanded in MEM supplemented with 10% heat inactivated 
FBS. 
Determination of Urokinase Production 
The secretion of urokinase activity into the cell 
culture medium from the fifteen antisense colonies 
selected by filter immunoblot assay were quantitated by a 
chromogenic substrate assay following the activation of 
plasminogen to plasmin. Table 11 shows that antisense 
clones s, 10, 11, and 12 (ACS, AClO, ACll, and AC12) 
secreted lower amounts of urokinase than other clones. 
The secretion of urokinase activity of these four 
antisense clones was confirmed by 125r-f ibrin plate assay 
as shown in Figure 20 and Table 12. Of four antisense 
clones, clone 10 (AClO) and clone S (ACS) secreted 
approximately 70% of urokinase when compared to a mixed 
population of B16-Fl0 or pSV2-neo transfected B16-F10 
cells. 
The incorporations of pSV2-ASuPA and pSV2-neo 
Table 11. Quantification of secreted plasminogen 
activator activity from B16-Fl0 transfected cells by 
chromogenic substrate assaya 
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Clone No Absorbance Clone No Absorbance 
(Mean ± SD) (Mean ± SD) 
ACl 0.51 ± 0.03 AC9 0.58 ± 0.06 
AC2 0.56 ± 0.04 AClO 0.36 ± 0.02 
AC3 0.46 ± 0.02 ACll 0.46 ± 0.03 
AC4 0.56 ± 0.03 AC12 0.45 ± 0.02 
AC5 0.49 ± 0.01 AC13 0.68 ± 0.04 
AC6 0.70 ± 0.04 AC14 0.61 ± 0.03 
AC7 0.47 ± 0.02 AC15 0.59 ± 0.02 
ACS 0.40 ± 0.03 
Bl6-Fl0 0.51 + 0.02 Bl6-Fl0Neo 0.52 ± 0.03 
aB16-FlO or transfected Bl6-Fl0 cell conditioned media 
were incubated for 16 hours with the plasmin specific 
chromogenic substrate S-2251 (H-D-Val-Leu-Lys-p-
nitroanilide) and DFP treated plasminogen. After the 
incubation, the p-nitroaniline absorbance, corresponding 
to substrate hydrolysis by plasmin, was measured. 
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Figure 20. Secreted plasminogen activator activity 
of B16-F10 and pSV2-ASuPA transf ected B16-F1 cells 
determined by 1251-fibrin plate assay 
Conditioned media from Bl6-Fl0, 816-FlO 
transfected with pSV2-neo, antisense clones 8 (ACS), 
10 (AClO), 11 (ACll), and 12 (AC12) of transfected 
with pSV2-ASuPA were incubated with DFP-treated 
plasminogen in 125r-fibrin plate. The activity of 
plasmin, which was activated from plasminogen by the 
urokinase produced from conditioned media, was 
measured by the released soluble 125r-f ibrin 
degradation product. Nonspecific activity was 
measured in the absence of cell conditioned media 
and subtracted from the experimental value. 
Plasminogen activator activity was expressed in pg 
secreted to conditioned medium per cell per hour. 
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Table 12. Quantification of secreted plasminogen 
activator (PA) activity of Bl6-Fl0 and transfected Bl6-F10 
cells as determined by 125I-fibrin plate assaya 
Cell 
B16-Fl0 
B16-F10 (pSV2-neo) 
ACS (pSV2-ASuPA) 
AClO (pSV2-ASuPA) 
ACll (pSV2-ASuPA) 
AC12 (pSV2-ASuPA) 
Secreted PA activityb 
(Mean ± SD) 
12.0 ± 0.37e 
11.9 ± 0.83e 
8.33 ± 0.59c,d 
8.71 ± 0.71c,d 
9.34 ± 0.46c,d 
9.60 ± 0.37c,d 
acell conditioned media collected from B16-F10 and pSV2-
neo or pSV2-ASuPA transfected B16-Fl0 cells were incubated 
with DFP-treated plasminogen in 125r-fibrin plate. The 
ability of plasmin, which was activated from plasminogen 
by the plasminogen activator produced from conditioned 
media, was measured by the released soluble 125r-fibrin 
degradation product. 
bPlasminogen activator activity is expressed in 1x10-2 pg 
secreted to conditioned medium per cell per hour. 
cAC8, AClO, ACll, and AC12 are significantly different 
from B16-F10 at p = 0.008, 0.0022, 0.0016, and 0.0014 
respectively. 
dAcs, AClO, ACll, and AC12 are significantly different 
from B16-F10 (pSV2-neo) at p = 0.0037, 0.0031, 0.0095, and 
0.0012 respectively. 
eNot significantly different (p = 0.95) 
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plasmids into the Bl6-Fl0 cell genomic DNA of antisense 
clones 10 and 8 were assayed by Southern blot 
hybridization assay as shown in Figure 21. The DNAs were 
prepared from the antisense clones 10 and 8 and pSV2-neo 
transfected cells. To detect the pSV2-neo and pSV2-ASuPA 
incorporation, DNAs were digested with PstI, separated by 
electrophoresis, transferred to nitrocellulose filter, and 
probed with 32P-labeled HpaI-PstI pSV2-ASuPA fragment. 
The digestion of pSV2-ASuPA with PstHI generates four DNA 
bands with base pairs of 2418, 1430, 958, and 923 pairs 
and 32P-labeled probe hybridizes with all the band. The 
digestion of pSV2-neo with PstI generates two DNA bands 
with base pairs of 3540 and 958 and the probe hybridizes 
with both bands. Figure 21 shows that antisense clones 
AClO and ACS demonstrate the restriction endonuclease 
digested bands identical to those of pSV2-ASuPA plasmid. 
The densitomer scan of autoradiograghs (data not shown) 
suggests less than 5 copy numbers of pSV2-ASuPA were 
present in the transfected antisense clones 10 or 8 cells. 
Lung Colonization Assay 
To assess the effect of inhibition of urokinase 
production on lung colonization, antisense clones 10 and 8 
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Figure 21. Southern blot hybridization analysis of 
DNA i&olated from antisense clones 10 (AC10) and 8 
(AC8) of pSV2-ASuPA transfected cells, B16-F10, and 
B16-F10 pSV2-neo transfected cells 
DNAs were isolated from antisense clone 10 
(AClO) and S (ACS) of pSV2-ASuPA transfected B16-F10 
cells, pSV2-neo transfected cells, or untransfected 
Bl6-Fl0 cells. The DNAs (10 ug) were cleaved with 
PstI and electrophoresed through O.S% agarose gel. 
A control pSV2-ASuPA plasmid preparation was 
similarly digested with PstI and different amounts 
were loaded onto the same gel. The DNAs were 
transferred to nitrocellulose and probed with 32P-
labeled HpaI-PstI fragment of pSV2-ASuPA. Lanes 1 
and 2 contain DNA made from 7 x 106 , and 3.5 x 106 
cells AClO. Lanes 3 and 4 contain DNA made from 7 x 
10 6 and 3.5 x 106 cells of ACS. Lane 5 contain DNAs 
made from 7 x 10 6 cells of untransf ected Bl6-Fl0 and 
lane 6 from 3.5 x 10 6 of pSV2-neo transfected cells. 
Lanes 7, s, and 9 contain pSV2-ASuPA DNA of 10, 5, 2 
ng respectively. 
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were injected to mice through tail vein. Table 13 shows 
the results of the lung colonization assay of antisense 
clones 10 and 8. AClO and ACS cells which produced 
approximately 70% of urokinase compared to Bl6-Fl0 cells 
showed a 40 to 42% decrease in the ability to form lung 
tumors (p = 0.0016 and 0.0019 respectively by Student's t 
test and p < 0.005 and p < 0.005 by the Mann Whitney u-
test respectively. The pSV2-neo transfected Bl6-Fl0 cell 
mixture showed a similar lung colonization ability 
compared to untransfected Bl6-Fl0 cells (Fidler, 1983). 
Thus, as shown in Bl6-Fl cell transfection, transfection 
alone does not affect metastatic potential of the Bl6-Fl0 
cells. 
Figure 22 shows the gross appearance of typical 
lungs dissected from control mice (injected with pSV2-neo 
transfected cells) and experimental mice (injected with 
pSV2-neo and pSV2-ASuPA transfected cells). It was 
observed the majority of tumors from the control mice were 
smaller than that from the experimental mice. Thus, all 
the tumors from the control and experimental mice were 
grouped into three different sizes (small, medium, and 
large) and number of tumors in each size category were 
counted. Small size tumor indicates less than 0.2 mm, 
medium size between 0.2 mm and 0.7 mm, and large size more 
Table 13. Lung colonization by B16-F10 murine melanoma 
cells transfected with human preprourokinase antisense 
gene in a SV40 expression vectora 
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Vector Number of Tumors Mean ± S.E. 
Experiment .l 
pSV2-neo 32,34,55,56,71,76,80,90 72.8 + 6.8b 
(control) 91,92,97,99 
pSV2-neo & 27,28,28,29,33,34,37,40, 43.0 ± 4.9b 
pSV2-ASuPA 45,45,60,67,86 
(AClO) 
Experiment 2-
pSV2-neo 116,136,148,155,189, 212.5 ± 21.5C (control) 192,245,254,275,306,321 
pSV2-neo & 51,71,73,101,126,135, 123.1 ± 12.8c 
pSV2-ASuPA 150,152,156,166,173 
(AC8) 
aAnimals were tail vein injected with 1x10 5 B16-Fl0 
transfected cells. Mice were killed 17 days later and 
number of lung metastatic foci was counted. 
bDifferent at p = 0.0016 by Student t-test and p < 0.01 
by the Mann Whitney U-test (nonparametric rank sum test). 
cDifferent at p = 0.0019 by Student t-test and p < 0.01 
by the Mann Whitney U-test. 
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Figure 22. Gross appearance of typical lungs 
dissected from control (left) and experimental 
(right) mice 
Control mice were injected with 105 Bl6-Fl0 
cells transfected with pSV2-neo and experimental 
mice received 105 antisense clone 10 (AClO) cells 
transfected with the pSV2-neo and pSV2-ASuPA 
plasmids. 
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than 0.7 mm in diameter. Figure 23 and Table 14 shows the 
size of metastatic tumors in lungs expressed in percent of 
tumor numbers in the different size categories. It was 
observed that more than 60% of tumors produced by 
experimental mice belong to large size category, while 
Bl6-Fl0 pSV2-neo transf ected cells produce mainly small 
and medium size tumors. 
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Figure 23. Size of metastatic tumors in murine lung 
from mice tail-vein injected with B16-Fl0 
transf ected cells 
Size of the lung tumors from control and 
experimental mice were determined and divided into 
three categories, small (<0.2 mm in diameter), 
medium (0.2 mm-0.7 mm), and large (>0.7 mm). 
Results are expressed in percent of tumor numbers in 
the different size category. 
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Table 14. Size of metastatic tumors in murine lung from 
mice tail-vein injected with B16-F10 transfected cellsa 
Cells 
Injected 
pSV2-neo 
(control) 
pSV2-neo & 
pSV2-ASuPA 
(AClO) 
pSV2-neo 
(control) 
pSV2-neo & 
pSV2-ASuPA 
(ACS) 
Percentage of tumors in size category 
Small Medium Large 
(Mean± S.E.) 
32.8 ± 2.86 48.2 ± 2.37 21.2 ± 2.75 
13.9 ± 1.81 25.2 ± 2.07 60.1 ± 3.16 
37.0 + 1.86 47.0 ± 2.49 16.l ± 2.70 
11.2 + 2.27 24.1 ± 2.14 64.7 ± 3.42 
asize of the lung tumors from control and experimental 
groups were measured and divided into three size 
categories, small (<0.2 mm in diameter), medium (0.2 mm-
0.7 mm), and large (>0.7 mm). Results are expressed in 
percent ± S.E. of tumor numbers in the different size 
category. 
CHAPTER V 
DISCUSSION 
We have shown in this work direct evidence for the 
importance of urokinase in tumor cell metastasis by 
modifying the gene expression in murine B16 melanoma tumor 
cells. The metastatic potential of the cells transfected 
with preprourokinase cDNA was dramatically enhanced 
compared to the control cells in vivo. In addition, the 
cells transfected with antisense cDNA of urokinase gene 
showed decreased metastatic potential in vivo. 
Cell Lines Selected for the Study 
B16 melanoma cell lines, B16-Fl and B16-F10, which 
metastasize to form pulmonary tumor nodules (Fidler, 1973) 
were used in this study. The B16 tumor lines have been 
established by Fidler (1973) by injecting tumor cells i.v. 
into syngeneic C57BL/6 mice, isolating, and then culturing 
the secondary lung tumor nodules in tissue culture. The 
B16-Fl cell line was passaged once through the selection 
137 
138 
process, while Bl6-Fl0 cell line was passaged ten times. 
The Bl6-Fl cell line possesses low ability to form 
metastatic lung colonies, while the Bl6-Fl0 cell line 
shows high ability when injected i.v. into syngeneic 
C57BL/6 mice (Fidler, 1975). These cell lines have been 
used by a number of investigators to determine a 
quantitative correlation between the production of 
plasminogen activator and their capacity to metastasize. 
Wang et al. (1980) reported quantitative differences in 
plasminogen activator production between low metastatic 
Bl6-Fl and high metastatic Bl6-Fl0 melanoma sublines, the 
latter producing more plasminogen activator activity than 
the Bl6-Fl cells. Nicolson et al. (1976) however showed 
contradictory results, reporting a lack of correlation in 
plasminogen activator activities between variant Bl6 
sublines such as Bl6-Fl, Bl6-F5, Bl6-Fl0, and Bl6-Fl3. 
Expression of Human Urokinase Gene in 816-Fl Melanoma 
Cells 
The DNA-mediated transfection technique (Graham and 
van der Ed, 1973) was used as a means of introducing 
foreign genes into the murine melanoma cells. The optimal 
transfection conditions as described in the Methods 
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section were developed specifically for B16 cell lines. 
The human preprourokinase gene was successfully expressed 
in B16-Fl cells under the control of an SV40 early gene 
promoter (pSV2 vector). The expression of the 
incorporated preprourokinase gene was found to be stable. 
No loss of human prourokinase expression was observed even 
after over 20 passages of the transfected cells. 
The data in Figure 16 and 17 show that clone 7 and 
clone 10 of pSV2-uPA transfected cells secrete a three to 
four fold increase in plasminogen activator activity. The 
enhanced plasminogen activator activity in clone 7 and 
clone 10 was shown to be specifically related to human 
urokinase and not to the endogenous murine urokinase based 
on the following observations: (i) The clones were 
initially selected based soly on their high production of 
human urokinase, by a filter immunoblot assay using a 
polyclonal antibody to human urokinase (Figure 9), (ii) In 
a second selection, from those clones selected by the 
filter immunoblot assay, clones 7 and 10 were shown to 
produce the highest level of human urokinase by ELISA 
using a monoclonal antibody to human urokinase (Table 1). 
Further characterization of the selected cells showed: (i) 
Urokinase produced by clone 7 was glycosylated as expected 
for the human urokinase (Figure 16). The murine urokinase 
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is not a glycoprotein (Belin, et al., 1985), (ii) Southern 
blot hybridization analysis (Figure 10) demonstrated that 
multiple copies of the human urokinase gene were 
incorporated in the genomic DNA of clone 7. The human 
urokinase was selectively identified under the blotting 
conditions used for the assay. The murine urokinase gene 
did not hybridize with the human cDNA probe under the 
conditions used, and, (iii) Northern blot hybridization 
analysis (Figure 5) demonstrated human urokinase gene 
expressions by clone 7 and clone 10. 
Glycosylation of Human Urokinase .by Murine Cells 
The result of concanavalin A affinity 
chromatography (Figure 14) demonstrates that the human 
urokinase, produced by the transfected murine Bl6-Fl 
cells, is glycosylated. The murine urokinase gene lacks a 
glycosylation site (Belin et al., 1985) and is therefore 
not a glycoprotein. It is not surprising that the human 
gene product would be glycosylated since human urokinase 
contains a glycosylation site in its amino acid sequence 
(Holmes et al., 1985; Ricco et al., 1985). A carbohydrate 
side chain, containing at least four glucosamine and two 
galactosame residues, was reported at asparagine in 
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position 144 of the human urokinase B chain (Steffens et 
al., 1982). 
Lack of Binding of Human Urokinase to Murine Receptor 
As depicted in Figure 15, human urokinase does not 
bind to cell surface receptor sites on the murine B16-Fl 
cells. It is not known whether the lack of binding is the 
result of the glycosylation of human urokinase, or due to 
the other changes in the structure of the urokinase that 
prevents the human urokinase from binding to the mouse 
receptors. The observation that human urokinase does not 
bind to murine cell receptors is in agreement with other 
studies that reported a lack of cross-species binding of 
urokinase to cell surface receptors. Huate et al. (1987) 
reported no significant binding of human prourokinase to 
mouse spermatozoa. Most recently, Estreicher et al. 
(1989) demonstrated that human, mouse, and porcine 
urokinase bind to the corresponding cell receptors of the 
same species, while human urokinase failed to bind to 
murine MSV-3T3 cells and murine urokinase did not bind to 
human HeLa cells. 
Experimental Model for in vivo Metastasis Assay 
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To assay the metastatic potential of the 
transf ected Bl6-Fl cells expressing the human urokinase 
gene in vivo, the lung colonization and spontaneous 
metastasis assays were employed. In the lung colonization 
assay, mice were i.v. injected through the tail vein, and 
2-3 weeks later the animals were sacrificed and tumor 
nodules on the lung surface were counted under a 
dissecting microscope (Fidler, 1975). This assay measures 
tumor cell extravasation from the blood stream, invasion 
of basement membrane and extracellular matrix, and then 
growth into pulmonary tumors. In the spontaneous 
metastasis model, tumor cells injected in the foot pad of 
the mouse, grow into a primary tumor site and metastasize 
as secondary tumors to the lung (Fidler, 1978). This 
assay tests the full metastatic process in which the tumor 
cells intravasate through the capillary endothelial walls, 
survive in the circulation, extravasate from the 
capillaries through the basement membrane, and invade the 
extracellular matrix to establish a new tumor site. 
The Effect of Increased Expression of Urokinase on Lung 
Colonization Potentials 
Three of the clones (clones 7, 8, and 10) among the 
human preprourokinase transfected Bl6-Fl cells, were 
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chosen for in vivo metastatic assay. All of them showed a 
dramatic increase in lung colonization following tail vein 
inoculation (Table 5 and 6). The ELISA and chromogenic 
substrate assays for plasminogen activator confirmed the 
human urokinase activity in the cells from the lung 
nodules (Table 9 and 10). These results clearly show that 
the increased lung colonization potential of the clones 7, 
8, and 10 is due to the human urokinase produced by the 
pSV2-uPA transfected cells. Since the cells were solely 
selected for their ability to secrete human urokinase 
which does not bind to cell surface receptors, the issue 
of whether urokinase acts to promote metastasis on the 
cell surface or at locations away from the surf ace can be 
addressed. Our results demonstrate that the increased 
secretion of human urokinase activity strongly promotes 
metastasis in vivo. These results are in agreement with 
those recently reported by Cajot §..t. al. {1989). These 
authors transf ected the human urokinase gene into mouse L 
cells and showed a correlation between the modulation of 
prourokinase gene expression and the degradation of 
extracellular matrix by in vitro invasion through a 
basement membrane like material, Matrigel. Their results 
demonstrated that urokinase binding to the cell surf ace is 
not required for the increased degradation and invasion of 
144 
the extracellular matrix. These authors did not assay 
their cells in an in vivo model for metastasis. Axelrod 
et al. (1989} also recently demonstrated that their ras 
transformed murine NIH3T3 cells, transfected with 
recombinant human urokinase, produced 30-fold elevation in 
urokinase activity and manifested an increased invasion 
rate in an in vitro basement membrane assay. They also 
showed that the transfected cells had a sixfold increase 
in pulmonary metastatic lesions after i.v. injection into 
nude mice. 
Other authors however support the hypothesis that 
cell surface-localized urokinase activity is critical for 
tumor cell metastasis. Ossowski (1988} demonstrated that 
a saturation of human tumor cell, HeLa, receptors with 
exogenous human urokinase enhanced the invasion of the 
chick embryo chorioallantoic membrane. This suggests that 
urokinase binding to its receptor is important for the 
increased invasive potential of the tumor cells. A recent 
study by Hearing et al. (1988) demonstrated the presence 
of urokinase activity on the cell surface of B16 melanoma 
cells by immunofluorescence. The authors also reported 
that the preincubation of these cells expressing urokinase 
with an antibody to urokinase caused a reduction in their 
lung colonization ability when injected through the tail 
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vein of mice. Based on these data, the authors argued 
that cell surface localized urokinase activity has a 
critical role in lung colonization. However, the 
statistical significance of their data does not appear 
conclusive. In Table 2 of their report, they tested the 
effect of urokinase specific antibodies on pretreated Bl6 
cells in 12 separate experiments. Out of 12 experiments, 
the authors reported that three experiments showed no 
significant difference between the two groups using 
student t test at p ~ 0.05. However, by a Wilcoxon non-
parametric analysis of their experimental data, only two 
of the twelve experiments with anti-urokinase pretreated 
cells showed a significant decrease (at p ~ 0.05) in lung 
colonization as compared to the controls. In our study, 
we show that the human urokinase does not bind to the 
murine cell surface receptor, yet it clearly promotes 
metastasis. 
The role of the cell surf ace urokinase receptors 
may serve to focus the enzyme activity at critical sites 
on the cell surface. The binding of urokinase to its 
receptor, however, may also serve different functions than 
to promote metastasis. For example, it has been suggested 
that urokinase may bind to cells and act as a cell mitogen 
to induce cell proliferation (Kirchheimer et gl., 1987; 
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Takada and Takada, 1989; Kirchheimer et al., 1989). 
Regardless of the role of the cell surf ace associated 
urokinase, the results in this report show that an 
increase in the unbound, secreted form of human urokinase 
dramatically increased spontaneous metastasis and lung 
colonization by the Bl6-Fl cells. Future investigation 
that would help define the role of the urokinase receptor 
may involve cloning the urokinase receptor gene and its 
subsequent transfection into Bl6 cells. Such study would 
help elucidate the effect of urokinase cell surface 
receptor binding in invasion and metastasis in vivo. 
The lung colonization data of the clones 7, 8, and 10 in 
Table 5 and 6 and increased urokinase secretion of these 
clones infer that the increase in lung colonization by 
Bl6-Fl cells is directly related to an increased urokinase 
activity. A comparison of the plasminogen activator 
activity of Bl6-Fl cells, Bl6-Fl pSV2-uPA transfected 
cells (clone 7 and clone 10), and Bl6-Fl0 cells show that 
the clone 7 cells produce plasminogen activator activity 
equal to that of the Bl6-Fl0 cells (Table 2 and 3). In 
addition, the lung colonization potential for Bl6-Fl0 
cells is similar to that observed for the clone 7 cells 
(Schultz et al., 1988). 
A positive correlation between production of 
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plasminogen activator and a spontaneous metastatic 
potential for Bl6-Fl and Bl6-Fl0 cells has been previously 
reported (Wang et al., 1980). This earlier report, 
however, while showing a correlative increase in 
plasminogen activator production with increased 
spontaneous metastasis, was not based on a known increase 
in the expression of a single specific gene. Multiple 
differences have been reported between Bl6-Fl and Bl6-Fl0 
cells besides the differences in urokinase production. 
For example, there are differences in membrane lipid 
composition (Schroeder and Gardiner, 1984), in the 
expression of a 72 Kd glycosylated protein by Bl6-Fl0 
cells and not by Bl6-Fl (Kimura and Xiang, 1986), and in 
response of lung colonization to the monoclonal antibodies 
produced to tumor-associated antigens of Bl6-Fl or Bl6-Fl0 
cells (Herd, 1987). In addition, Bl6-Fl0 cells showed an 
increased glycosyltransferase activity as compared to Bl6-
Fl counterparts (Bosmann et .9..1.., 1974) and Bl6-Fl0 cells 
have a greater propensity to form in vitro aggregates with 
artificially disaggregated lung cells than Bl6-Fl cells 
(Nicolson and Winkelhake, 1975). 
The selection of the clones in this study was based 
solely on the ability of transfected cells to produce 
secreted human urokinase. The secreted human urokinase in 
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the B16-Fl cell line is shown to raise the metastatic 
potential of B16-Fl cells to that of B16-F10. This 
finding supports the conclusion that increase in urokinase 
activity is sufficient to explain the difference in 
metastatic potential between B16-F10 and Bl6-Fl cells. 
Blood-borne metastasis is a multiple step process 
which may be subdivided into several steps: (i) detachment 
of malignant tumor cells from the original tumor mass, 
(ii) invasion through the extracellular matrix and 
basement membrane with intravasation through the capillary 
endothelial walls, (iii) travel of tumor cells through the 
circulation, (iv) arrest in the capillary beds of the 
target tissue, (v) extravasation from the capillaries 
through the basement membrane and extracellular matrix, 
and (vi) implantation and growth of secondary tumor cells 
at a new site. The most critical steps in the metastatic 
process, where proteolytic enzymes have a role, appears to 
be the intravasation and extravasation steps (Liotta et 
al., 1982). 
The hypothesis that urokinase plays an important 
role in intravasation comes from the earlier work of 
Ossowski and Reich (1983) who showed that an antibody to 
human urokinase only inhibited lung colonization in the 
chick embryo when human tumor cells were placed on the 
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chorioallantoic membrane. Ossowski (1988) later reported 
in this model, a lack of urokinase effect on the 
extravasation step of metastasis by showing that the 
urokinase antibody did not inhibit metastasis when human 
tumor cells were directly injected into a chick embryo 
vein, as opposed to the cells being placed on the 
chorioallantoic membrane. These experiments support the 
argument that urokinase is important in the intravasation 
step, but not in the extravasation step. 
The argument of Ossowski agrees with the current 
interpretation of the role of fibrin in metastasis. It 
has been argued that coagulation and the formation of 
microthrombi might promote the attachment of tumor cells 
to the capillary walls of the target organ, forming a 
stationary phase of tumor cells which allows time for the 
extravasation of tumor cells to occur (Dano et al., 1985; 
Markus et al., 1984; Harvey et al., 1988). Urokinase, 
which can promote fibrin degradation through plasmin 
mediated fibrinolysis, would act against the formation of 
this protective stationary phase. Subsequently high 
urokinase activity in the extravasation step should lead 
to a decrease in lung colonization (Markus et al., 1984). 
In fact, Markus et al. (1983) compared the secretion of 
urokinase between the primary and metastatic tumors of 
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different types and found that urokinase secretion by 
metastatic tumors were lower than those of primary tumors. 
Harvey et al. (1988) also made similar observations which 
led to the proposal that reduced secretion of urokinase of 
metastatic tumors might provide a distinct advantage to 
tumor cells destined to initiate metastatic foci, and may 
contribute to the ability of circulating cancer cells to 
lodge in the blood vessels of the target organs. This 
hypothesis is also supported by the study of Gunji and 
Gorelik (1988) who demonstrated that the presence of 
fibrin deposition on tumor cells protected them from 
immunological destruction. However, this hypothesis does 
not agree with other reports. Iwakawa et al. (1986) 
demonstrated that an anticoagulant, which suppresses 
coagulation via inhibition of thrombin (which activates 
fibrinogen to fibrin) increased, rather than decreased, 
the number of lung colonies after i.v. injection of tumor 
cells. Ostrowski et al. (1986) reported similar findings 
that, mice implanted with mini-isopump infusion of a 
thrombin inhibitor produced increased B16 melanoma lung 
colonization. 
The results of the lung colonization assay (Table 5 
and 6) in this study, clearly shows an increase in 
urokinase activity by the C7, ClO, and C8 clones of the 
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pSV2-uPA transf ected cells which caused a dramatic 
increase in lung colonization ability. The lung 
colonization assay by tail vein injection (Table 5 and 6) 
measures the extravasation step of the metastatic process, 
as the tumor cells are directly injected into the blood, 
circumventing the earlier steps of the metastatic process. 
our conclusion that urokinase is important in the 
extravasation step of metastasis is consistent with the 
recent similar observations by Axelrod et al. (1989), that 
H-ras-transformed NIH3T3 cells expressing high levels of 
urokinase activity were more efficient in lung that 
increased plasminogen activator activity in rat mammary 
adenocarcinoma cells correlated with their lung 
colonization ability. 
The increase in secreted urokinase activity also 
provided the clone 7 cells with an ability to 
spontaneously metastasize from a primary tumor in the foot 
pad (Table 8). The spontaneous metastasis assay measures 
the ability of tumor cells to intravasate through the 
capillary endothelial walls, survive in the circulation, 
extravasate from the capillaries through the basement 
membrane, and invade the extracellular matrix to establish 
a new tumor site. These results are in agreement with 
earlier work by Wang et al. (1980) who demonstrated that 
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high plasminogen activator production by B16-Fl0 subline 
cells contributed to spontaneous metastasis, whereas B16-
Fl cells of low plasminogen activator production, had 
decreased pulmonary metastases. 
The increased spontaneous metastatic ability of 
clone 7 (Table 8) might be due to (i) the increase in the 
ability of the clone 7 cells to extravasate, as shown by 
the colonization assay (Table 5), (ii) the acquisition of 
colonization. Another report that support this hypothesis 
is the earlier study by Carlsen et al. (1984) which showed 
an increased ability to intravasate, or (iii) the increase 
in ability for both intravasation and extravasation. If 
urokinase activity was essential only in the extravasation 
step, then the ability of clone 7 to spontaneously 
metastasize may be simply due to the increased ability to 
extravasate. Whether the secreted form of urokinase 
activity is controlling the intravasation as well as the 
extravasation steps in the metastatic process remains to 
be clarified. Models that specifically isolate the 
intravasation step need to be developed in order to 
determine precisely how urokinase affects this step in the 
metastatic process. 
The cells secreting lower amounts of human 
urokinase (pSV2-neo transfected B16-Fl or C12 of pSV2-neo 
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and pSV2-uPA transfected cells) produce predominantly 
melanotic tumors as shown in Table 7. In contrast, the 
lung nodules formed by the cells secreting higher amounts 
of human urokinase consist of mixtures of amelanotic and 
melanotic tumors. In all three clones (clones 7, 10, and 
8) the lesions predominantly demonstrated the amelanotic 
phenotype. 
Phenotypic change cannot be attributed to the pSV2-
neo transfection since all the clones contain the pSV2-neo 
gene. The overproduction of urokinase may be responsible 
for the expression of this phenotype since the only 
difference between these groups is the amount of human 
urokinase secretion. Therefore high amounts of urokinase 
secretion in B16-Fl cells might inhibited melanin 
synthesis/production. The absence of the pigment in 
amelanotic tumor is reported to be the result of 
deficiency of tyrosinase activity (Slominski et al., 1987; 
Bennett et gl., 1986) even though some investigators 
reported that tyrosine activity did not correlate in vitro 
with melanin synthesis in K1735 SW-1 cells (Price et al., 
1988). 
A possible link between the high urokinase 
production and the metastatic potential may be the state 
of differentiation of the B16 cells. It has been 
154 
argued that more malignant cells are less differentiated 
(Bennett et al., 1986). In the B16 melanoma cell lines, 
melanin formation may correlated with differentiation. 
Thus amelanotic cells are less differentiated and also 
more metastatic. Urokinase production may affect the 
metastatic potential of a cell by changing its state of 
differentiation. However B16-F10 cells secrete a similar 
amount of urokinase as C7 cells but produce melanotic lung 
nodules. 
Several reports have linked melanin synthesis with 
a reduction in tumor cell proliferation (Gray~ al., 
1964; Lotan and Lotan, 1980). Other investigators have 
also suggested a positive correlation between tumor cell 
malignancy and the amelanotic phenotype in B16 cell lines 
(Romsdahl and Hsu, 1972; Lotan and Lotan, 1980). Our 
study confirmed these reports by showing that transfected 
cells secreting human urokinase undergo a phenotypic shift 
to cells that are more metastatic and form amelanotic 
colonies. 
The Effect of Inhibition of Urokinase Production in the 
Lung Colonization Potential 
If urokinase is required for tumor cell 
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colonization (Table 5 and 6), then the inhibition of 
urokinase activity should lead to a reduction in 
metastasis. By transfection of B16-F10 cells with an 
antisense urokinase gene, it may be possible to evaluate 
the effects of inhibiting urokinase gene expression on the 
metastatic process. B16-F10 melanoma cells of high 
metastatic potential were transfected with a plasmid 
containing human urokinase in the antisense direction 
(pSV2-ASuPA). The antisense clones 10 (AClO) and 8 (AC8) 
cells which produced 30% less urokinase activity were 
selected (Table 11, 12 and Figure 20). A Southern blot 
hybridization assay showed the incorporation of the 
antisense plasmid into the genomic DNA of these cells 
(Figure 21). Tail vein injection by these two clones 
showed a 40% reduction in lung colonization (Table 13). 
These results are in agreement with our previous 
experiments in which pSV2-uPA transf ected clones of Bl6-Fl 
cells showed increased urokinase production and increased 
lung colonization. Taken together these two results give 
supporting evidence that urokinase has an essential role 
in extravasation process of lung colonization by B16 
melanoma cells. This is in contrast to the results 
reported in the chorioallantoic membrane experiment which 
concluded that urokinase does not play a role in the 
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extravasation step (See previous discussion, Ossowski and 
Reich, 1983). 
The human urokinase gene transf ected C7 clone 
showed that approximately 150 copies of the urokinase gene 
was incorporated in Bl6-Fl cell DNA genome. After 
transfection of the antisense gene (pSV2-ASuPA) with the 
same SV40 expression vector, a small copy number of 
antisense urokinase genes were shown to be incorporated in 
the Bl6-Fl0 genomic DNA in the most inhibited cell colony. 
The difficulty of observing high copy number for 
incorporation of the antisense gene might be explained by 
the necessity of urokinase expression for cell viability. 
Cells with higher copies of incorporated antisense 
urokinase gene might fail to survive, hence escape 
detection. It has been proposed that urokinase is a 
growth stimulant in various cell lines by several 
investigators (Kirchheimer et al., 1987; Kirchheimer et 
al., 1989; Tanaka and Tanaka, 1989). Earlier study showed 
the production of plasminogen activator reached maximum 
during the logarithmic growth of transformed 3T3 cells and 
decreased as the cells reach the confluence (Jaken and 
Black, 1979). It was also shown that the production of 
urokinase correlated with the proliferative state of the 
melanoma cells (Grimmaldi et al., 1986). 
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An attempt to demonstrate antisense mRNA expression 
by Northern blot hybridization was made. However, it was 
not possible to detect the antisense transcript in the 
pSV2-ASuPA transf ected cells because of low abundance of 
antisense mRNAs. A more sensitive assay to demonstrate 
the presence of the antisense transcript would be to use 
the polymerase chain reaction (PCR) amplification, 
following reverse transcriptase treatment, to convert mRNA 
to cDNA (Saiki et al., 1988). 
The variation in the numbers of lung colonies 
between the control groups in Experiment 1 and 2 did not 
closely coincide, as is shown in Table 13. This may be 
the result of the use of different lots of animals or the 
use of cells from different time period. Since the 
control group was always tested in identical manner to the 
experimental group for each experiment, the important 
consideration for interpreting the data is the relative 
number of metastases for both control and experimental 
animals in any one set of experiments carried out at the 
same time and with the same lot of cells and animals. The 
variation in average numbers of lung colonies in each of 
the two separate experiments carried out at different time 
periods should not affect the conclusions of this work. 
Table 14 and Figure 22 and 23 show that the 
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metastatic lung tumors from the mice injected with 
antisense clones 10 or 8 were larger than those in control 
mice containing cells transfected with the pSV2-neo 
plasmid alone. This result suggests that decreased 
urokinase production inhibits metastasis but not the 
growth of tumors. 
Future studies to assess the role of urokinase in 
metastasis would be to regulate urokinase activity by 
means of plasminogen activator inhibitors (PAis). Several 
workers have shown that there are at least three 
immunologically distinct PAis, including PAI-1, PAI-2, and 
protease nexin (Loskutoff et al., 1983; Scott et al., 
1985; Sprengers and Kluft, 1987). These proteins 
inactivate both urokinase and tissue-type plasminogen 
activators by forming covalent complexes with the active 
site serine residues of the plasminogen activators 
(Andreasen et al., 1986). PAI-1 is an efficient inhibitor 
of both urokinase and tissue plasminogen activators. It 
has been purified (van Mourik et al., 1984) and its cDNA 
has been sequenced (Ny et al., 1986). PAI-2, which reacts 
more rapidly with urokinase than with tissue type 
plasminogen activator, has also been purified (Astedt et 
al., 1985) and the full length cDNA sequence has been 
determined (Ye et al., 1987). Future studies could 
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transfect cloned PAI-1 and PAI-2 genes into metastatic 
cells to evaluate their role in metastasis. It could be 
predicted that PAI-1 and PAI-2 are metastatic suppresser 
genes, in the same way as TIMP appears to be a metastatic 
repressor protein (Khokha et al., 1988). 
CHAPTER VI 
SUMMARY 
Metastasis is a process in which tumor cells detach 
from their primary site(s), invade through the surrounding 
tissue, and give rise to new lesions at sites distant from 
the primary tumor(s). Urokinase may have an important 
role in tumor cell metastasis. It has a proteolytic 
enzyme activity which can promote degradation of 
extracellular matrix and basement membrane. In this 
study, the role of urokinase in tumor cell metastasis was 
examined by modifying the urokinase gene expression in 
tumor cells. 
A SV40 expression vector containing the human 
preprourokinase gene (plasmid pSV2-uPA) was constructed 
and cotransfected with a selection marker gene (pSV2-neo) 
into murine Bl6-Fl melanoma cells of low metastatic 
potential. The expression of the human urokinase gene was 
demonstrated by a filter immunoblot assay and an ELISA 
using a monoclonal antibody to human urokinase. Southern 
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blot hybridization analysis of the clone expressing the 
highest level of human urokinase showed that the pSV2-uPA 
plasmid was incorporated in approximately 150 copies. 
These cells exhibited a 3 to 4-fold increase in secreted 
urokinase activity. The human urokinase synthesized by 
the murine cells was found to be glycosylated. 
Furthermore, it was shown that human urokinase does not 
bind to the murine Bl6-Fl cell surface urokinase receptor 
sites. Thus the human urokinase is simply constitutively 
synthesized and secreted by the transf ected murine 
melanoma cells. 
In the lung colonization assay which measures tumor 
cell extravasation from the blood and subsequent pulmonary 
tumor growth, the pSV2-uPA transfected cells showed a 4 to 
18-fold increase in the ability to form lung tumors. In 
the spontaneous metastatic assay, which measures the full 
metastatic process, the transfected cells showed an 
absolute ability to metastasize (12 out of 12 mice), while 
control cells showed a low ability to metastasize (only 2 
out of 11 mice). These results clearly show that an 
increase in secreted urokinase activity promotes both lung 
colonization and spontaneous metastasis. 
In addition, Bl6-Fl0 murine melanoma cells of high 
metastatic ability were cotransfected with a 265 base pair 
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cDNA containing the leader sequence of the human 
preprourokinase gene in an antisense direction (plasmid 
pSV2-ASuPA) and pSV2-neo. Two of the antisense clones 
secreted approximately 70% of the urokinase activity of 
control cells. Southern blot hybridization analysis 
confirmed the incorporation of pSV2-ASuPA into the genomic 
DNA. In the lung colonization assay, the cells containing 
antisense urokinase cDNA showed a 40 to 42% decrease in 
the ability to form lung tumors. These results support 
the conclusion that urokinase is an important promoter of 
the extravasation step in tumor cell metastasis. It was 
also observed that the majority of tumors from the control 
mice (injected with pSV2-neo transfected cells) were 
smaller than those of the experimental mice (injected with 
pSV2-neo and pSV2-ASuPA transfected cells). This result 
indicates that inhibition of urokinase production may 
decrease the metastatic potential and correspondingly 
increase the tumorigenic potential of murine melanoma 
cells. 
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APPENDIX 
APPENDIX 
Prior to the use of pSV2 expression vector 
pSV2-uPA (shown in Figure 3), the plasmid pRdzbuktt 
(shown in Figure 1) which contains Rous sarcoma virus 
(RSV) long terminal repeats (LTR) promoter was tested for 
the preprourokinase gene expression. The expression 
vector containing RSV LTR promoter had been previously 
used in a variety of murine cell lines other than Bl6 cell 
lines (Gorman et al., 1982). 816-Fl cells were 
cotransfected with pSV2-neo and pRdzbuktt, shocked with 
glycerol, and grown in the presence of Geneticin as 
described previously. The DNAs were prepared from the 
surviving cells of pSV2-neo and pRdzbuktt transfected or 
pSV2-neo transfected cells. To detect the pSV2-neo 
incorporation, DNAs were digested with HindIII, or double 
digested with HindIII/BamHI or HindIII/PstI, separated by 
electrophoresis, transferred to nitrocellulose filter, and 
probed with 32P-labeled pSV2-neo fragment. The digestion 
of pSV2-neo with HindIII generates one single DNA band of 
5729 base pairs and 32P-labeled probe hybridizes with the 
183 
184 
band. The double digestion of pSV2-neo with HindIII and 
~I generates two DNA bands with base pairs of 3386 and 
2346 and the probe hybridizes with the 2346 band. The 
double digestion of pSV2-neo with HindIII and PstI 
generates five DNA bands with base pairs of 1883, 1430, 
958, 923, and 535 and the probe hybridizes with the 1430 
and 923 bands. Figure 24 shows that the cells transfected 
with pSV2-neo alone or cotransfected with pSV2-neo and 
pRdzbuktt demonstrate the restriction endonuclease 
digested bands identical to those of pSV2-neo plasmid. 
To detect the pRdzbuktt incorporation, Southern 
blot hybridization assay was performed using the 32P-
labeled sacI and HindIII fragment of pRdzbuktt as a probe. 
However, in Figure 25, Southern blot hybridization assay 
failed to show pRdzbuktt incorporation to the genomic DNA 
of the transfected cells. The production of plasminogen 
activator by the pRdzbuktt transfected cells was 
determined by the f luorogenic substrate assay and compared 
to pSV2-neo transfected or untransfected cells. As shown 
in Table 15, the cells transfected with pRdzbuktt produced 
same amounts of plasminogen activator as pSV2-neo 
transfected or 816-Fl cells. Taking Figure 25 and Table 
15 together, the results show that the plasmid pRdzbuktt 
was not incorporated into the genomic DNA of 816-Fl cells, 
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Figure 2~. Southern blot analysis of DNA isolated 
from pSV2-neo and pRdzbuktt transf ected cells to 
detect the pSV2-neo incorporation 
DNAs were isolated from pSV2-neo transfected 
or pRdzbuktt transfected Bl6-Fl cells. The DNAs (10 
ug) were cleaved with HindIII or double digested 
with HindIII and BamHI or HindIII and PstI and 
electrophoresed through 0.8% agarose gel. A control 
pSV2-neo plasmid preparation was similarly digested 
with the same enzymes. The DNAs were transferred to 
nitrocellulose and probed with 32P-labeled PvuII 
fragment of pSV2-neo. Lanes 1,2,3 contain DNA made 
from the plasmid pSV2-neo, lanes 4,5,6 contain DNA 
made from pSV2-neo transfected cells, and lanes 
7,8,9 contain DNAs made from the pSV2-neo and 
pRdzbuktt transfected cells. DNAs in lanes 1,4,7 
were digested with HindIII, DNAs in lanes 2,5,8 were 
double digested with HindIII and BamHI, and DNAs in 
lanes 3,6,9 were double digested with HindIII and 
Pstr. 
m.w. 
marker 
6.56 
4.36 
2.32 
2.03 
pSV2-neo 
H H+B H+P 
1 2 3 
TF-pSV2-neo 
H - H+B - H+P 
-
4 5 6 
TF-pRdzbuktt 
and pSV2-neo 
H H+B B+P 
7 8 9 
1 8 6 
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Figure ?5. Southern blot analysis of DNA isolated 
from pSV2-neo and pRdzbuktt transf ected cells to 
detect the pRdzbuktt incorporation 
DNAs were isolated from pSV2-neo transf ected 
or pRdzbuktt transfected Bl6-Fl cells. The DNAs (10 
ug) were cleaved with HindIII or double digested 
with HindIII and SacI or HindIII and PstI and 
electrophoresed through 0.8% agarose gel. A control 
pRdzbuktt plasmid preparation was similarly digested 
with the same enzymes. The DNAs were transferred to 
nitrocellulose and probed with 32P-labeled HindIII-
PstI fragment of pRdzbuktt. Lanes 1,2,3 contain DNA 
made from the plasmid pRdzbuktt, lanes 4,5,6 contain 
DNA made from pSV2-neo transfected cells, and lanes 
7,8,9 contain DNAs made from the pSV2-neo and 
pRdzbuktt transfected cells. DNAs in lanes 1,4,7 
were digested with HindIII, DNAs in lanes 2,5,8 were 
double digested with HindIII and SacI, and DNAs in 
lanes 3,6,9 were double digested with HindIII and 
PstI. 
m.w. pRdzbuktt 
marker H H+S H+P 
6.56 
4.36 
2.32 
2.03 
1 2 3 
TF-pSV2-neo 
H H+S B+P 
4 5 6 
TF-pRdzbuktt 
and pSv2-neo 
H B+S H+P 
7 8 9 
188 
189 
Table 15. Quantification of plasminogen activator (PA) 
production by B16-Fl, B16-F10, and transfected Bl6-Fl 
cells with pSV2-neo or pRdzbuk.tt as determined by 
f luorogenic substrate assaya 
Cell PA activityb 
(Mean ± SD) 
B16-Fl 
B16-Fl (pSV2-neo) 
B16-Fl (pRdzbuktt) 
B16-Fl0 
0.57 
0.56 
0.51 
1.38 
± 0 _09c,d,e 
± 0.13c 
± o.o7d 
± o.1oe 
aB16-Fl, B16-F10, and B16-Fl transfected cells with pSV2-
neo or pRdzbuktt were incubated with fluorogenic substrate 
for plasminogen activator, methoxysuccinyl-L-Gly-L-Gly-L-
Arg-7-amino-4-methylcoumarin HCl. The ability of 
plasminogen activator to release 7-amino-4-methylcoumarin 
(AMC) from the substrate was measured. 
bPlasminogen activator activity is expressed by the slope 
of linear release of AMC under the assay conditions. 
cNot significantly different (p = 0.92) 
dNot significantly different (p = 0.31) 
esignificantly different (p = 0.000) 
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which subsequently failed to produce human urokinase. 
Another attempt was made to express the human 
preprourokinase gene by the plasmid, pCLH3AXBPV, which 
contains bovine papilloma virus (BPV-1) with MT-1 
(metallothreonine) promoter (Figure 4). The insertion of 
human preprourokinase gene into the pCLH3AXBPV is shown in 
Figure 5 and the final plasmid structure, pCLH3AXBPV-uPA, 
is shown in Figure 6. The plasmid was similarly 
transfected to Bl6-Fl cells and a fibrin overlay assay was 
performed. The fibrin overlay assay tests the transient 
expression of urokinase gene prior to its incorporation to 
the genomic DNA. The optimum condition for the assay was 
developed for Cl27 cells (mammary tumor cell line of an 
RIII mouse obtained from American Tissue Culture Center, 
No. CRL1616) transfected with pCLH3AXBPV-uPA as described 
by Reddy et al. (1987). The results in Figure 26 
demonstrate the absence of plasminogen activator activity 
in the fibrin agarose matrix which indicates the cells 
transfected with plasmid pCLH3AXBPV-uPA did not produce 
urokinase. In contrast, Cl27 cells transfected with 
pCLH3AXBPV-uPA gave positive results with respect to pSV2-
neo transfected controls (data not shown). 
The efficiency of gene transfer under the control 
of the viral regulatory sequence might have limitations 
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Figure 26. Fibrin overlay assay to detect the 
transient expression of urokinase gene by the 
transf ection of the plasmid pCLHJXBPV-uPA to B16-F1 
cells 
B16-Fl cells transfected with pCLH3AXBPV-uPA 
were mixed with agarose in MEM supplemented with 
10% heat inactivated FBS containing fibrinogen and 
thrombin and incubated at 37°C overnight. The 
ability of plasmin, which was activated from 
plasminogen by the urokinase, was detected by the 
clearing zones of fibrin degradations on the 
agarose matrix. Plasminogen was supplied from the 
FBS in the reaction mixture and f ibrinogen was 
activated to fibrin by thrombin. The cells 
transfected with pCLH3AXBPV-uPA shows the absence 
of clearing zones which indicate that the cells did 
not produce urokinase (top). A control which contained 
several drops of urokinase solution showed clearing 
circles of fibrin degradation (bottom). 
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which affect its application to certain cell lines. For 
example, it has been suggested that the flanking long 
terminal repeats (LTRs) as well as BPV vectors may 
interfere with transcriptional regulation of the inserted 
foreign gene sequences that could lead to a lack of 
expression in certain cell lines (Howard, 1983). 
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